PT J
AU Trevenzoli, IH
   Valle, MMR
   Machado, FB
   Garcia, RMG
   Passos, MCF
   Lisboa, PC
   Moura, EG
AF Trevenzoli, I. H.
   Valle, M. M. R.
   Machado, F. B.
   Garcia, R. M. G.
   Passos, M. C. F.
   Lisboa, P. C.
   Moura, E. G.
TI Neonatal hyperleptinaemia programmes adrenal medullary function in adult rats: effects on cardiovascular parameters
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID body-weight; leptin treatment; adipose-tissue; food-intake; catecholamine synthesis; tyrosine-hydroxylase; metabolic syndrome; thyroid-function; obesity; receptor
AB Epidemiological studies have shown a strong correlation between stressful events (nutritional, hormonal or environmental) in early life and development of adult diseases such as obesity, diabetes and cardiovascular failure. It is known that gestation and lactation are crucial periods for healthy growth in mammals and that the sympathoadrenal system is markedly influenced by environmental conditions during these periods. We previously demonstrated that neonatal hyperleptinaemia in rats programmes higher body weight, higher food intake and hypothalamic leptin resistance in adulthood. Using this model of programming, we investigated adrenal medullary function and effects on cardiovascular parameters in male rats in adulthood. Leptin treatment during the first 10 days of lactation (8 mu g 100 g(-1) day(-1), S.C.) resulted in lower body weight (6.5%, P < 0.05), hyperleptinaemia (10-fold, P < 0.05) and higher catecholamine content in adrenal glands (18.5%, P < 0.05) on the last day of treatment. In adulthood (150 days), the rats presented higher body weight (5%, P < 0.05), adrenal catecholamine content (3-fold, P < 0.05), tyrosine hydroxylase expression (35%, P < 0.05) and basal and caffeine-stimulated catecholamine release (53% and 100%, respectively, P < 0.05). Systolic blood pressure and heart rate were also higher in adult rats (7% and 6%, respectively, P < 0.05). Our results show that hyperleptinaemia in early life increases adrenal medullary function in adulthood and that this may alter cardiovascular parameters. Thus, we suggest that imprinting factors which increase leptin and catecholamine levels during the neonatal period could be involved in development of adult chronic diseases.
C1 Univ Fed Rio de Janeiro, Dept Physiol, Roberto Alcantara Gomes Biol Inst, Rio De Janeiro, Brazil.
   Univ Fed Juiz de Fora, Inst Biol Sci, Dept Biol, Juiz De Fora, MG, Brazil.
   Univ Fed Rio de Janeiro, Inst Nutr, Appl Nutr Dept, Rio De Janeiro, Brazil.
C3 Universidade Federal do Rio de Janeiro; Universidade Federal de Juiz de Fora; Universidade Federal do Rio de Janeiro
RP Lisboa, PC (corresponding author), Univ Estado Rio de Janeiro, Inst Biol, Dept Ciencias Fisiol, 5 Andar,Av 28 Setembro 87, BR-20551030 Rio De Janeiro, RJ, Brazil.
EM pclisboa@uerj.br
CR Almeida JR, 2005, LIFE SCI, V77, P1307, DOI 10.1016/j.lfs.2004.12.043
   Armitage JA, 2004, J PHYSIOL-LONDON, V561, P355, DOI 10.1113/jphysiol.2004.072009
   Barker DJP, 2004, J AM COLL NUTR, V23, P588S, DOI 10.1080/07315724.2004.10719428
   BARKER DJP, 1995, EUR J CLIN INVEST, V25, P457, DOI 10.1111/j.1365-2362.1995.tb01730.x
   Bates SH, 2004, J MOL MED, V82, P12, DOI 10.1007/s00109-003-0494-z
   Bates SH, 2003, TRENDS ENDOCRIN MET, V14, P447, DOI 10.1016/j.tem.2003.10.003
   BAYNE K, 1996, PHYSIOLOGIST, V38, P208
   Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004
   Bouret SG, 2004, ENDOCRINOLOGY, V145, P2621, DOI 10.1210/en.2004-0231
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cao GY, 1997, AM J PHYSIOL-ENDOC M, V273, PE448, DOI 10.1152/ajpendo.1997.273.2.E448
   Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0
   Cravo CD, 2002, HORM METAB RES, V34, P400, DOI 10.1055/s-2002-33473
   FISCHBECK KL, 1987, J NUTR, V117, P1967, DOI 10.1093/jn/117.11.1967
   FLATT JP, 1995, AM J CLIN NUTR, V62, P820, DOI 10.1093/ajcn/62.4.820
   Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861
   Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376
   Gallardo N, 2005, ENDOCRINOLOGY, V146, P4934, DOI 10.1210/en.2005-0220
   Glasow A, 1998, J CLIN ENDOCR METAB, V83, P4459, DOI 10.1210/jc.83.12.4459
   Huxley R, 2002, LANCET, V360, P659, DOI 10.1016/S0140-6736(02)09834-3
   Inoue M, 2003, CELL CALCIUM, V33, P19, DOI 10.1016/S0143-4160(02)00178-1
   KELNER KL, 1985, NEUROCHEM INT, V7, P373, DOI 10.1016/0197-0186(85)90128-7
   Kim J, 2004, SOLID STATE ELECTRON, V48, P175, DOI 10.1016/S0038-1101(03)00113-8
   Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508
   LAFONTAN M, 1993, J LIPID RES, V34, P1057
   Langley-Evans SC, 1999, LIFE SCI, V64, P965, DOI 10.1016/S0024-3205(99)00022-3
   Lisboa PC, 2006, HORM METAB RES, V38, P295, DOI 10.1055/s-2006-925390
   Lisboa PC, 2003, AM J PHYSIOL-ENDOC M, V284, PE1172, DOI 10.1152/ajpendo.00513.2002
   Malendowicz LK, 2004, INT J MOL MED, V13, P829
   Martins ACP, 2004, LIFE SCI, V74, P3211, DOI 10.1016/j.lfs.2003.10.034
   McKenzie S, 2002, EUR J NEUROSCI, V15, P1485, DOI 10.1046/j.1460-9568.2002.01990.x
   Molendi-Coste O, 2006, ENDOCRINOLOGY, V147, P3050, DOI 10.1210/en.2005-1331
   Nowak KW, 2002, INT J MOL MED, V9, P31
   Passos MCF, 2004, HORM METAB RES, V36, P625, DOI 10.1055/s-2004-825927
   Passos MCF, 2000, NUTR RES, V20, P1603, DOI 10.1016/S0271-5317(00)00246-3
   Rahmouni K, 2005, HYPERTENSION, V45, P9, DOI 10.1161/01.HYP.0000151325.83008.b4
   RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701
   Reaven G, 2004, ENDOCRIN METAB CLIN, V33, P283, DOI 10.1016/j.ecl.2004.03.002
   Sahu A, 2004, ENDOCRINOLOGY, V145, P2613, DOI 10.1210/en.2004-0032
   Sanchez A, 2003, PHARMACOL RES, V48, P607, DOI 10.1016/S1043-6618(03)00241-X
   Satoh N, 1999, DIABETES, V48, P1787, DOI 10.2337/diabetes.48.9.1787
   Savoia C, 2004, MED CLIN N AM, V88, P39, DOI 10.1016/S0025-7125(03)00122-6
   Stallknecht B, 2004, DAN MED BULL, V51, P1
   Steinberg GR, 2004, AM J PHYSIOL-ENDOC M, V286, PE57, DOI 10.1152/ajpendo.00302.2003
   Takekoshi K, 2001, ENDOCRINOLOGY, V142, P290, DOI 10.1210/en.142.1.290
   Takekoshi K, 2001, ENDOCRINOLOGY, V142, P4861, DOI 10.1210/en.142.11.4861
   Teixeira CV, 2003, HORM METAB RES, V35, P367, DOI 10.1055/s-2003-41359
   Teixeira CV, 2002, J NUTR BIOCHEM, V13, P493, DOI 10.1016/S0955-2863(02)00197-3
   Toste FP, 2006, BRIT J NUTR, V95, P830, DOI 10.1079/BJN20061726
   Utsunomiya K, 2001, J NEUROCHEM, V76, P926, DOI 10.1046/j.1471-4159.2001.00123.x
   VANDERTUIG JG, 1985, AM J PHYSIOL, V248, PE607, DOI 10.1152/ajpendo.1985.248.5.E607
   Vickers MH, 2005, ENDOCRINOLOGY, V146, P4211, DOI 10.1210/en.2005-0581
   Waterland RA, 1999, AM J CLIN NUTR, V69, P179
   Yanagihara N, 2000, BIOCHEM PHARMACOL, V59, P1141, DOI 10.1016/S0006-2952(00)00240-9
   Young JB, 2002, TRENDS ENDOCRIN MET, V13, P381, DOI 10.1016/S1043-2760(02)00661-6
   Yura S, 2005, CELL METAB, V1, P371, DOI 10.1016/j.cmet.2005.05.005
   Zambrano E, 2006, J PHYSIOL-LONDON, V571, P221, DOI 10.1113/jphysiol.2005.100313
NR 57
TC 43
Z9 45
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD APR 15
PY 2007
VL 580
IS 2
BP 629
EP 637
DI 10.1113/jphysiol.2006.126151
PG 9
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 156KN
UT WOS:000245646900025
PM 17218354
DA 2025-04-28
ER

PT J
AU Thom, E
AF Thom, E.
TI The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article
DE chlorogenic acid; coffee; glucose; diet
ID caffeic acid; consumption; tolerance; inhibitors; tea
AB The results from a clinical study performed in 12 healthy volunteers with different coffee products containing glucose show that instant coffee enriched with chlorogenic acid induced a reduction in the absorption of glucose of 6.9% compared with the control. No such effects were seen with normal or decaffeinated instant coffee. In a second, comparative, randomized, double-blind, 12-week study we investigated the effect on the body mass of 30 overweight people, compared with normal instant coffee. The average losses in mass in the chlorogenic acid enriched and normal instant coffee groups were 5.4 and 1.7 kg, respectively. We conclude that chlorogenic acid enriched instant coffee appears to have a significant effect on the absorption and utilization of glucose from the diet. This effect, if the coffee is used for an extended time, may result in reduced body mass and body fat when compared with the use of normal instant coffee.
C1 ETC Res & Dev, N-0774 Oslo, Norway.
RP Thom, E (corresponding author), ETC Res & Dev, Stasjonsveien 5A, N-0774 Oslo, Norway.
EM erlingthom@etc.as
CR Unknown -, 2006, BMC COMPLEM ALTERN M, V0, P0
   Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874
   Bidel S, 2006, HORM METAB RES, V38, P38, DOI 10.1055/s-2006-924982
   Clifford MN, 1999, J SCI FOOD AGR, V79, P362, DOI 10.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>3.0.CO;2-D
   Clifford MN, 2000, J SCI FOOD AGR, V80, P1033, DOI 10.1002/(SICI)1097-0010(20000515)80:7<1033::AID-JSFA595>3.0.CO;2-T
   Cornelis MC, 2006, JAMA-J AM MED ASSOC, V295, P1135, DOI 10.1001/jama.295.10.1135
   Andersen LF, 2006, AM J CLIN NUTR, V83, P1039, DOI 10.1093/ajcn/83.5.1039
   Greenberg JA, 2005, INT J OBESITY, V29, P1121, DOI 10.1038/sj.ijo.0802999
   Greenberg JA, 2006, AM J CLIN NUTR, V84, P682, DOI 10.1093/ajcn/84.4.682
   Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360
   Herling AW, 1998, AM J PHYSIOL-GASTR L, V274, PG1087, DOI 10.1152/ajpgi.1998.274.6.G1087
   Higdon JV, 2006, CRIT REV FOOD SCI, V46, P101, DOI 10.1080/10408390500400009
   Hiltunen LA, 2006, EUR J CLIN NUTR, V60, P1222, DOI 10.1038/sj.ejcn.1602441
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   Lafay S, 2006, J NUTR, V136, P1192, DOI 10.1093/jn/136.5.1192
   Lafay S, 2005, INT J VITAM NUTR RES, V75, P119, DOI 10.1024/0300-9831.75.2.119
   Lafay S, 2006, BRIT J NUTR, V96, P39, DOI 10.1079/BJN20061714
   Lopez-Garcia E, 2006, AM J CLIN NUTR, V83, P674, DOI 10.1093/ajcn.83.3.674
   MELETIS CD, 2006, ALTERN COMPLEMEN FEB, V0, P7
   Ochiai R, 2004, HYPERTENS RES, V27, P731, DOI 10.1291/hypres.27.731
   Olthof MR, 2001, AM J CLIN NUTR, V73, P532
   Olthof MR, 2001, J NUTR, V131, P66, DOI 10.1093/jn/131.1.66
   Simon C, 2000, ARCH BIOCHEM BIOPHYS, V373, P418, DOI 10.1006/abbi.1999.1560
   WELSCH CA, 1989, J NUTR, V119, P1698, DOI 10.1093/jn/119.11.1698
NR 24
TC 203
Z9 226
U1 1
U2 42
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-0605
EI 1473-2300
J9 J INT MED RES
JI J. Int. Med. Res.
PD NOV-DEC 15
PY 2007
VL 35
IS 6
BP 900
EP 908
DI 10.1177/147323000703500620
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 237NV
UT WOS:000251382700020
PM 18035001
DA 2025-04-28
ER

PT J
AU Sugiyama, T
   Xie, DW
   Graham-Maar, RC
   Inoue, K
   Kobayashi, Y
   Stettler, N
AF Sugiyama, Takehiro
   Xie, Dawei
   Graham-Maar, Rose C.
   Inoue, Kazuo
   Kobayashi, Yasuki
   Stettler, Nicolas
TI Dietary and lifestyle factors associated with blood pressure among US adolescents
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Article; Proceedings Paper
DE adolescent; blood pressure; body mass index; cross-sectional studies; exercise; life style; nutrition; nutrition surveys; obesity; television
ID cardiovascular mortality; sedentary behavior; pulse pressure; metaanalysis; hypertension; childhood; obesity; sodium; supplementation; potassium
AB Purpose: To identify modifiable lifestyle factors associated with blood pressure among U.S. adolescents. Methods: A cross-sectional study was conducted of 4508 12-19-year-old respondents of the 1999-2002 National Health and Nutrition Examination Survey. Systolic and diastolic blood pressure (SBP and DBP) were measured and adjusted for gender, age, and height using z-scores (SBPZ and DBPZ). Body mass index (BMI) was adjusted for gender and age (BMIZ). Questionnaires were used to measure nutrient intake (carbohydrate, protein, saturated and unsaturated fat, sodium, potassium, calcium, magnesium, fiber, and caffeine) and activities (physical activities and sedentary activities, including television watching). Results: In the adjusted model (R-2 = .115), SBPZ was higher by .022 standard deviation (SD) (95% confidence interval [CI]:.007-038, equivalent to similar to .2 mmHg) per 1-hour increments in sedentary activities; higher by .244 SD (.198 - .289, similar to 2.6 mmHg) per 1 SD of BMIZ; and lower by .099 SD (-.192 to -.006, similar to 1.1 mmHg) per 100 g of carbohydrate intake. Unexpectedly, BMIZ was negatively associated with DBPZ (-.078 per 1 SD, -.114 to -.043, similar to.9 mmHg). Conclusions: Among U.S. adolescents, sedentary activities and BMI are positively associated with SBP after adjustment for confounding factors and mediators, while BMI is negatively associated with DBP. If confirmed by further studies, population-based interventions aimed at sedentary activities may be practical approaches to decrease SBP and the risk of obesity among adolescents.) 2007 Society for Adolescent Medicine. All rights reserved.
C1 Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA.
   Univ Tokyo, Fac Med, Tokyo 113, Japan.
   Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
   Univ Tokyo, Dept Publ Hlth, Tokyo, Japan.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Tokyo; University of Pennsylvania; University of Tokyo
RP Stettler, N (corresponding author), Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, N 1559,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM nstettle@cceb.med.upenn.edu
CR Unknown -, 1996, APPL LINEAR STAT MOD, V0, P0
   Appel LJ, 2006, HYPERTENSION, V47, P296, DOI 10.1161/01.HYP.0000202568.01167.B6
   APPEL LJ, 1993, ARCH INTERN MED, V153, P1429, DOI 10.1001/archinte.153.12.1429
   Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601
   Appel LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455, DOI 10.1001/jama.294.19.2455
   BAO WH, 1995, AM J HYPERTENS, V8, P657, DOI 10.1016/0895-7061(95)00116-7
   Beilin LJ, 2001, BLOOD PRESSURE, V10, P352, DOI 10.1080/080370501753400656
   Benetos A, 1997, HYPERTENSION, V30, P1410, DOI 10.1161/01.HYP.30.6.1410
   Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302
   CAPPUCCIO FP, 1995, AM J EPIDEMIOL, V142, P935, DOI 10.1093/oxfordjournals.aje.a117741
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   ELLIOTT P, 1988, BRIT MED J, V297, P319
   Epstein LH, 2002, J PEDIATR-US, V140, P334, DOI 10.1067/mpd.2002.122395
   EPSTEIN LH, 1995, HEALTH PSYCHOL, V14, P109, DOI 10.1037/0278-6133.14.2.109
   Falkner Bonita, 1997, AMERICAN JOURNAL OF CLINICAL NUTRITION, V65, P618S, DOI 10.1093/ajcn/65.2.618S
   Franklin SS, 1999, CIRCULATION, V100, P354, DOI 10.1161/01.CIR.100.4.354
   Gunnell DJ, 1998, AM J CLIN NUTR, V67, P1111, DOI 10.1093/ajcn/67.6.1111
   Kelley George A, 2003, PREV CARDIOL, V6, P8, DOI 10.1111/j.1520-037X.2003.01224.x
   Kuczmarski RJ, 2000, VITAL HLTH STAT, V0, PP1, DOI 10.1016/J.BBRC.2015.06.114
   Liu LJ, 2002, HYPERTENS RES, V25, P689
   Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590
   Moore LL, 2005, EPIDEMIOLOGY, V16, P4, DOI 10.1097/01.ede.0000147106.32027.3e
   MOTOYAMA T, 1989, HYPERTENSION, V13, P227, DOI 10.1161/01.HYP.13.3.227
   Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555
   PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460
   Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561
   ROCCHINI AP, 1989, NEW ENGL J MED, V321, P580, DOI 10.1056/NEJM198908313210905
   ROCCHINI AP, 1988, PEDIATRICS, V82, P16
   Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101
   SimonsMorton DG, 1997, HYPERTENSION, V29, P930, DOI 10.1161/01.HYP.29.4.930
   Sorof J, 2002, HYPERTENSION, V40, P441, DOI 10.1161/01.HYP.0000032940.33466.12
   Sorof JM, 2004, PEDIATRICS, V113, P475, DOI 10.1542/peds.113.3.475
   Streppel MT, 2005, ARCH INTERN MED, V165, P150, DOI 10.1001/archinte.165.2.150
   VanLeer EM, 1995, INT J EPIDEMIOL, V24, P1117, DOI 10.1093/ije/24.6.1117
   Weisberg S, 2005, APPLIED LINEAR REGRESSION, V3rd, P0, DOI 10.1002/0471704091
   Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624
   Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006
   WILLET W, 1998, NUTR EPIDEMIOLOGY, V0, P30
NR 39
TC 58
Z9 71
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1054-139X
EI 1879-1972
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD FEB 15
PY 2007
VL 40
IS 2
BP 166
EP 172
DI 10.1016/j.jadohealth.2006.09.006
PG 7
WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA 131SF
UT WOS:000243889500011
PM 17259057
DA 2025-04-28
ER

PT J
AU Ohta, Y
   Funayama, M
   Seino, H
   Sami, M
   Kanda, T
   Shoji, T
   Ohtake, Y
   Osada, K
AF Ohta, Yutaka
   Funayama, Makoto
   Seino, Hirotake
   Sami, Manabu
   Kanda, Tomomasa
   Shoji, Toshihiko
   Ohtake, Yasuyuki
   Osada, Kyoichi
TI Apple polyphenol improves lipid metabolism and insulin independence in obese rats
SO JOURNAL OF THE JAPANESE SOCIETY FOR FOOD SCIENCE AND TECHNOLOGY-NIPPON SHOKUHIN KAGAKU KOGAKU KAISHI
LA English
DT Article
DE apple; procyanidins; obesity; Zucker fatty rat; insulin resistance
ID green tea catechins; diet-induced obesity; mass-spectrometry; chlorogenic acid; gene-expression; liquid-chromatography; glucose-homeostasis; caffeic acid; procyanidins; cholesterol
AB We evaluated the effects of apple polyphenol (AP), of which the major components are procyanidins, on obesity and glucose tolerance using Zucker fatty rats (fa/fa). In this study, Zucker fatty rats were fed diets containing 0.2% or 1.0% apple polyphenol for 12 weeks. Visceral fat weight and triglyceride levels in blood and liver were reduced by AP intake. Glucose and insulin levels in blood also decreased, and the amount of fatty acids excreted into feces increased in dose-dependent manner. Furthermore, suppression of fatty acid synthase gene expression in the liver and increase of adiponectin gene expression in white adipose tissues were observed. These results indicate that AP improves lipid metabolism and insulin resistance.
C1 Hirosaki Univ, Fac Agr & Life Sci, Hirosaki, Aomori 036, Japan.
   Asahi Brewery Co Ltd, Fundamental Res Labs, Ibaraki 302, Japan.
C3 Hirosaki University; Asahi Group Holdings Ltd.
RP Ohta, Y (corresponding author), Hirosaki Univ, Fac Agr & Life Sci, 3 Bunkyo-cho, Hirosaki, Aomori 036, Japan.
EM yutaka.ohta@asahibeer.co.jp
CR AKAZOME Y, 2005, JPN PHARMACOL THER, V33, P893
   ALLAIN CC, 1974, CLIN CHEM, V20, P470
   Cabrera C, 2006, J AM COLL NUTR, V25, P79, DOI 10.1080/07315724.2006.10719518
   Crespy V, 2004, J NUTR, V134, P3431S, DOI 10.1093/jn/134.12.3431S
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   DROR Y, 1970, CLIN CHIM ACTA, V28, P291, DOI 10.1016/0009-8981(70)90093-8
   Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7
   Feng WY, 2006, CURR DRUG METAB, V7, P755, DOI 10.2174/138920006778520552
   FEUERS RJ, 1989, MECH AGEING DEV, V48, P179, DOI 10.1016/0047-6374(89)90049-3
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356
   Gonthier MP, 2006, BIOMED PHARMACOTHER, V60, P536, DOI 10.1016/j.biopha.2006.07.084
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   JEEJEEBHOY KN, 1970, CLIN BIOCHEM, V3, P157, DOI 10.1016/S0009--912(0()70)80021--2
   Kanda T, 1998, BIOSCI BIOTECH BIOCH, V62, P1284, DOI 10.1271/bbb.62.1284
   Kao Y, 2000, AM J CLIN NUTR, V72, P1232
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508
   Lafay S, 2006, J NUTR, V136, P1192, DOI 10.1093/jn/136.5.1192
   Lafay S, 2006, BRIT J NUTR, V96, P39, DOI 10.1079/BJN20061714
   Li RW, 2006, LIFE SCI, V79, P365, DOI 10.1016/j.lfs.2006.01.023
   Li RW, 2006, J ETHNOPHARMACOL, V104, P24, DOI 10.1016/j.jep.2005.08.045
   Liu XM, 2004, DIABETES CARE, V27, P839, DOI 10.2337/diacare.27.3.839
   Masukawa Y, 2006, J CHROMATOGR B, V834, P26, DOI 10.1016/j.jchromb.2006.02.008
   Matsui N, 2005, NUTRITION, V21, P594, DOI 10.1016/j.nut.2004.10.008
   MATSUMOTO N, 1993, BIOSCI BIOTECH BIOCH, V57, P525, DOI 10.1271/bbb.57.525
   Moller DE, 2005, ANNU REV MED, V56, P45, DOI 10.1146/annurev.med.56.082103.104751
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Nakamura Y, 2002, J HEALTH SCI, V48, P570, DOI 10.1248/jhs.48.570
   Nepokroeff C M, 1975, METHODS ENZYMOL, V35, P37, DOI 10.1016/0076-6879(75)35136-7
   OhnishiKameyama M, 1997, RAPID COMMUN MASS SP, V11, P31, DOI 10.1002/(SICI)1097-0231(19970115)11:1<31::AID-RCM784>3.0.CO;2-T
   Ohta Y, 2006, JOURNAL OF OLEO SCIENCE, V55, P305
   Osada K, 1999, BBA-GEN SUBJECTS, V1427, P337, DOI 10.1016/S0304-4165(99)00039-2
   Osada K, 2006, JOURNAL OF OLEO SCIENCE, V55, P79
   Osada K, 2006, LIPIDS, V41, P133, DOI 10.1007/s11745-006-5081-y
   Schoenlau Frank, 2001, INTERNATIONAL OPHTHALMOLOGY, V24, P161, DOI 10.1023/A:1021160924583
   Shoji T, 2006, J AGR FOOD CHEM, V54, P884, DOI 10.1021/jf052260b
   Shoji T, 2006, J CHROMATOGR A, V1102, P206, DOI 10.1016/j.chroma.2005.10.065
   Shoji T, 2004, FOOD CHEM TOXICOL, V42, P959, DOI 10.1016/j.fct.2004.02.008
   Shoji T, 2003, J AGR FOOD CHEM, V51, P3806, DOI 10.1021/jf0300184
   Tian WX, 2006, CURR MED CHEM, V13, P967, DOI 10.2174/092986706776361012
   Tsuda T, 1999, FEBS LETT, V449, P179, DOI 10.1016/S0014-5793(99)00407-X
   Tsuda T, 2005, BBA-MOL CELL BIOL L, V1733, P137, DOI 10.1016/j.bbalip.2004.12.014
   Tsuda T, 2006, BIOCHEM PHARMACOL, V71, P1184, DOI 10.1016/j.bcp.2005.12.042
   Tsuda T, 2004, BIOCHEM BIOPH RES CO, V316, P149, DOI 10.1016/j.bbrc.2004.02.031
   Wen X, 2006, DRUG METAB DISPOS, V34, P1786, DOI 10.1124/dmd.106.011122
   Wolfram S, 2005, ANN NUTR METAB, V49, P54, DOI 10.1159/000084178
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Yanagida A, 2000, J CHROMATOGR A, V890, P251, DOI 10.1016/S0021-9673(00)00614-2
NR 52
TC 5
Z9 5
U1 0
U2 18
PU JAPAN SOC FOOD SCIENCE TECHNOLOGY
PI IBARAKI-KEN
PA 2-1-12 KANNONDAI TSUKUBA-SHI, IBARAKI-KEN, 305-8642, JAPAN
SN 1341-027X
EI 
J9 J JPN SOC FOOD SCI
JI J. Jpn. Soc. Food Sci. Technol.-Nippon Shokuhin Kagaku Kogaku Kaishi
PD JUN 15
PY 2007
VL 54
IS 6
BP 287
EP 294
DI 
PG 8
WC Food Science & Technology
SC Food Science & Technology
GA 181FF
UT WOS:000247421600007
DA 2025-04-28
ER

PT J
AU Chiu, YH
   Lin, WY
   Wang, PE
   Chen, YD
   Wang, TT
   Warwick, J
   Chen, THH
AF Chiu, Yueh-Hsia
   Lin, Wen-Yuan
   Wang, Po-En
   Chen, Yao-Der
   Wang, Ting-Ting
   Warwick, Jane
   Chen, Tony Hsiu-Hsi
TI Population-based family case-control proband study on familial aggregation of metabolic syndrome: Finding from Taiwanese people involved in Keelung community-based integrated screening (KCIS no. 5)
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE metabolic syndrome; family case-control proband study; familial aggregation; environmental factors
ID insulin-resistance syndrome; type-2 diabetes-mellitus; young adulthood; risk; obesity; association; childhood; education; women; model
AB A population-based case-control proband study was undertaken to elucidate familial aggregation, independent environmental factors, and the interaction between them. A total of 7308 metabolic syndrome (MET-S) cases were identified from the Keelung community-based integrated screening programme between 1999 and 2002. The study has a case-control/family sampling design. A total of 1417 case probands were randomly selected from 3225 metabolic syndrome cases and the corresponding 2458 controls selected from 16,519 subjects without metabolic syndrome by matching on sex, age ( 3 years) and place of residence. The generalized estimation equation model was used to estimate odds ratios and corresponding 95% confidence intervals. The risk for having metabolic syndrome among family members for cases versus control probands was 1.56-fold (1.29-1.89) after controlling for significant environmental factors. Higher risk of metabolic syndrome was found in parents than spouse. Low education against high education had 2.06-fold (1.36-3.13) risk for metabolic syndrome. Betel quid chewing was positively associated with the risk of MET-S, with 1.99-fold (1.13-3.53) risk for 1-9 pieces and 1.76-fold (0.96-3.23) risk for > 10 pieces compared with non-chewer. Moderate and high intensity of non-occupational exercise led to 2 1.0% (OR= 0.79 (0.63-0.98)) and 26.0% (OR= 0.74 (0.59-0.94)) reduction in the risk for metabolic syndrome, respectively. The frequent consumption of vegetable reduced 24.0% (OR = 0.76 (0.62-0.92)) risk for MET-S. The frequent consumption of coffee was associated the increased risk for metabolic syndrome (OR = 1.32 (1.07-1.64)). The present study confirmed the risk of metabolic syndrome not only has the tendency towards familial aggregation but is affected by independent effect of environmental or individual correlates. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
C1 Natl Taiwan Univ, Div Biostat, Grad Inst Epidemiol, Inst Prevent Med,Coll Publ Hlth, Taipei 100, Taiwan.
   Hlth Bur Keelung City, Chilung, Taiwan.
   Hlth Bur Tainan Cty, Tainan, Taiwan.
   Canc Res UK Ctr Epidemiol Math & Stat, Wolfson Inst Prevent Med, London, England.
C3 National Taiwan University; Cancer Research UK; University of London; Queen Mary University London
RP Chen, THH (corresponding author), Natl Taiwan Univ, Div Biostat, Grad Inst Epidemiol, Inst Prevent Med,Coll Publ Hlth, Room 521,17 Hsuchow Rd, Taipei 100, Taiwan.
EM stony@episerv.cph.ntu.edu.tw
CR BAO WH, 1994, ARCH INTERN MED, V154, P1842
   Brancati FL, 1996, ANN EPIDEMIOL, V6, P67, DOI 10.1016/1047-2797(95)00095-X
   Brunner EJ, 1997, DIABETOLOGIA, V40, P1341, DOI 10.1007/s001250050830
   CARMELLI D, 1994, AM J HUM GENET, V55, P566
   Chen THH, 2006, AM J CLIN NUTR, V83, P688, DOI 10.1093/ajcn.83.3.688
   Chen THH, 2004, CANCER-AM CANCER SOC, V100, P1734, DOI 10.1002/cncr.20171
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Eriksson J, 1997, DIABETOLOGIA, V40, P125
   Guh JY, 2006, AM J CLIN NUTR, V83, P1313, DOI 10.1093/ajcn/83.6.1313
   Hidvégi T, 2001, DIABETES CARE, V24, P2013, DOI 10.2337/diacare.24.11.2013-a
   Hong YL, 1997, AM J HUM GENET, V60, P143
   Katzmarzyk PT, 2001, J CLIN EPIDEMIOL, V54, P190, DOI 10.1016/S0895-4356(00)00315-2
   Koch R, 2001, HUM HERED, V52, P171, DOI 10.1159/000053373
   Liang KY, 1996, GENET EPIDEMIOL, V13, P253, DOI 10.1002/(SICI)1098-2272(1996)13:3<253::AID-GEPI3>3.0.CO;2-7
   Liese AD, 1997, DIABETOLOGIA, V40, P963, DOI 10.1007/s001250050775
   Loos RJF, 2003, J CLIN ENDOCR METAB, V88, P5935, DOI 10.1210/jc.2003-030553
   Mayer EJ, 1996, AM J EPIDEMIOL, V143, P323
   Pereira MA, 2002, JAMA-J AM MED ASSOC, V287, P2081, DOI 10.1001/jama.287.16.2081
   Poulsen P, 2001, DIABETOLOGIA, V44, P537, DOI 10.1007/s001250051659
   Rennie KL, 2003, INT J EPIDEMIOL, V32, P600, DOI 10.1093/ije/dyg179
   Sargeant LA, 2000, INT J OBESITY, V24, P1333, DOI 10.1038/sj.ijo.0801383
   Schoeller DA, 1997, AM J CLIN NUTR, V66, P551, DOI 10.1093/ajcn/66.3.551
   Tung TH, 2004, DIABETOLOGIA, V47, P1776, DOI 10.1007/s00125-004-1532-2
   van Dam RM, 2002, ANN INTERN MED, V136, P201, DOI 10.7326/0003-4819-136-3-200202050-00008
   Wamala SP, 1999, DIABETES CARE, V22, P1999, DOI 10.2337/diacare.22.12.1999
   WHO, 2000, WHO TECHN REP SER, V894, P0
   *WHO, 2000, AS PERSP RED OB ITS, V0, P0
   Winkleby MA, 1998, JAMA-J AM MED ASSOC, V280, P356, DOI 10.1001/jama.280.4.356
   Yen AMF, 2006, AM J CLIN NUTR, V83, P1153, DOI 10.1093/ajcn/83.5.1153
NR 29
TC 15
Z9 16
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD MAR 15
PY 2007
VL 75
IS 3
BP 348
EP 356
DI 10.1016/j.diabres.2006.07.014
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 135OZ
UT WOS:000244164200013
PM 16935381
DA 2025-04-28
ER

PT J
AU Tupper, T
   Gopalakrishnan, G
AF Tupper, Traci
   Gopalakrishnan, Geetha
TI Prevention of diabetes development in those with the metabolic syndrome
SO MEDICAL CLINICS OF NORTH AMERICA
LA English
DT Article
ID life-style intervention; impaired glucose-tolerance; beta-cell function; cigarette-smoking; physical-activity; follow-up; postmenopausal women; insulin sensitivity; coffee consumption; prospective cohort
AB Metabolic syndrome is characterized by abnormal glucose levels, central obesity, hypertension, elevated triglycerides, and low HDL cholesterol. This article reviews available data regarding the impact of lifestyle modification and drug therapies on the progression to diabetes in high risk individuals, such as those with hypertension, dyslipidemia, obesity, and prediabetes. Lifestyle and pharmaco-logical interventions may alter metabolic parameters and impact progression to diabetes. However, the cost-effectiveness of these interventions are unclear.
C1 Brown Univ, Warren Alpert Med Sch, Providence, RI 02860 USA.
C3 Brown University
RP Gopalakrishnan, G (corresponding author), Brown Univ, Warren Alpert Med Sch, 1 Hoppin St,Suite 200, Providence, RI 02860 USA.
EM ggopala@lifespan.org
CR Abuissa H, 2005, J AM COLL CARDIOL, V46, P821, DOI 10.1016/j.jacc.2005.05.051
   Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   *AM COLL END TASK, 2003, ENDOCR PRACT, V9, P236
   Balkau B, 1999, DIABETIC MED, V16, P442
   Bosch J, 2006, NEW ENGL J MED, V355, P1551
   Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796
   Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Collins R, 2003, LANCET, V361, P2005
   Dahlöf B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3
   Davies MJ, 2002, JAMA-J AM MED ASSOC, V287, P2559, DOI 10.1001/jama.287.19.2559
   Diabetes Prevention Progam, 2005, DIABETES, V54, P1150
   *DPP, 2002, DIABETES CARE, V259, P2165
   Durbin RJ, 2004, DIABETES OBES METAB, V6, P280, DOI 10.1111/j.1462-8902.2004.0348.x
   Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7
   Eddy DM, 2005, ANN INTERN MED, V143, P251, DOI 10.7326/0003-4819-143-4-200508160-00006
   ERIKSSON KF, 1991, DIABETOLOGIA, V34, P891, DOI 10.1007/BF00400196
   Fontbonne A, 1996, DIABETES CARE, V19, P920, DOI 10.2337/diacare.19.9.920
   Frati AC, 1996, DIABETES CARE, V19, P112, DOI 10.2337/diacare.19.2.112
   Freeman DJ, 2001, CIRCULATION, V103, P357
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   Genuth S, 2003, DIABETES CARE, V26, P3160
   Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8
   Gillespie EL, 2005, DIABETES CARE, V28, P2261, DOI 10.2337/diacare.28.9.2261
   American Heart Association, 2005, CARDIOL REV, V13, P322
   Hamman RF, 2006, DIABETES CARE, V29, P2102, DOI 10.2337/dc06-0560
   Hanson RL, 2002, DIABETES, V51, P3120, DOI 10.2337/diabetes.51.10.3120
   HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302
   Herman WH, 2005, ANN INTERN MED, V142, P323, DOI 10.7326/0003-4819-142-5-200503010-00007
   Heymsfield SB, 2000, ARCH INTERN MED, V160, P1321, DOI 10.1001/archinte.160.9.1321
   Houston TK, 2006, BMJ-BRIT MED J, V332, P1064, DOI 10.1136/bmj.38779.584028.55
   Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433
   Hu G, 2004, ARCH INTERN MED, V164, P892, DOI 10.1001/archinte.164.8.892
   Iso H, 2006, ANN INTERN MED, V144, P554, DOI 10.7326/0003-4819-144-8-200604180-00005
   JAING R, 2002, JAMA-J AM MED ASSOC, V345, P790
   JANZON L, 1983, DIABETOLOGIA, V25, P86
   Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005
   Keech A, 2003, DIABETES CARE, V26, P2713, DOI 10.2337/diacare.26.10.2713
   Keen H, 1973, ADVANCES IN METABOLIC DISORDERS, V0, P521
   Kirkman MS, 2006, DIABETES CARE, V29, P2095, DOI 10.2337/dc06-0061
   Kitabchi AE, 2005, DIABETES, V54, P2404, DOI 10.2337/diabetes.54.8.2404
   Klein BEK, 2002, DIABETES CARE, V25, P1790, DOI 10.2337/diacare.25.10.1790
   Knowler WC, 2003, DIABETES CARE, V26, P977
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/nejmoa012512
   Koppes LLJ, 2005, DIABETES CARE, V28, P719, DOI 10.2337/diacare.28.3.719
   Li CL, 1999, DIABETIC MED, V16, P477, DOI 10.1046/j.1464-5491.1999.00090.x
   Lindström J, 2006, LANCET, V368, P1673, DOI 10.1016/S0140-6736(06)69701-8
   LONG SD, 1994, DIABETES CARE, V17, P372, DOI 10.2337/diacare.17.5.372
   Lynch J, 1996, ARCH INTERN MED, V156, P1307, DOI 10.1001/archinte.156.12.1307
   Manson JE, 2000, AM J MED, V109, P538, DOI 10.1016/S0002-9343(00)00568-4
   Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x
   Padwal R, 2005, DIABETES CARE, V28, P736, DOI 10.2337/diacare.28.3.736
   Pereira MA, 2002, JAMA-J AM MED ASSOC, V287, P2081, DOI 10.1001/jama.287.16.2081
   RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555
   SARTOR G, 1980, DIABETES, V29, P41, DOI 10.2337/diabetes.29.1.41
   Sattar N, 2003, CIRCULATION, V108, P414, DOI 10.1161/01.CIR.0000080897.52664.94
   Schulze MB, 2007, ARCH INTERN MED, V167, P956, DOI 10.1001/archinte.167.9.956
   Sever PS, 2004, DRUGS, V64, P43, DOI 10.2165/00003495-200464002-00005
   Shai I, 2006, DIABETES CARE, V29, P1585, DOI 10.2337/dc06-0057
   SHIMOKATA H, 1989, JAMA-J AM MED ASSOC, V261, P1169, DOI 10.1001/jama.261.8.1169
   Smith B, 2006, DIABETES CARE, V29, P2385, DOI 10.2337/dc06-1084
   STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002
   Tenenbaum A, 2004, CIRCULATION, V109, P2197, DOI 10.1161/01.CIR.0000126824.12785.B6
   The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group, 2002, JAMA, V288, P2981, DOI 10.1001/jama
   Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   van Dam RM, 2006, DIABETES CARE, V29, P398, DOI 10.2337/diacare.29.02.06.dc05-1512
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   van Dam RM, 2002, DIABETES CARE, V25, P417, DOI 10.2337/diacare.25.3.417
   van Dam RM, 2002, ANN INTERN MED, V136, P201, DOI 10.7326/0003-4819-136-3-200202050-00008
   Vermes E, 2003, CIRCULATION, V107, P1291, DOI 10.1161/01.CIR.0000054611.89228.92
   Wannamethee SG, 2001, DIABETES CARE, V24, P1590, DOI 10.2337/diacare.24.9.1590
   Weickert MO, 2006, DIABETES CARE, V29, P775, DOI 10.2337/diacare.29.04.06.dc05-2374
   Wing RR, 1998, DIABETES CARE, V21, P350, DOI 10.2337/diacare.21.3.350
   Xiang AH, 2006, DIABETES, V55, P517, DOI 10.2337/diabetes.55.02.06.db05-1066
   Yang W, 2001, CHIN J ENDOCRINOL ME, V17, P131
   Yusuf S, 2005, CIRCULATION, V112, P48, DOI 10.1161/CIRCULATIONAHA.104.528166
   Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882
NR 79
TC 5
Z9 6
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0025-7125
EI 1557-9859
J9 MED CLIN N AM
JI Med. Clin. N. Am.
PD NOV 15
PY 2007
VL 91
IS 6
BP 1091
EP +
DI 10.1016/j.mcna.2007.06.006
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA 235HO
UT WOS:000251224600007
PM 17964911
DA 2025-04-28
ER

PT J
AU Oben, J
   Enonchong, E
   Kuate, D
   Mbanya, D
   Thomas, TC
   Hildreth, DJ
   Ingolia, TD
   Tempesta, MS
AF Oben, Julius
   Enonchong, Ebangha
   Kuate, Dieudonne
   Mbanya, Dora
   Thomas, Tiffany C.
   Hildreth, DeWall J.
   Ingolia, Thomas D.
   Tempesta, Michael S.
TI The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article
ID catechin-polyphenols; density lipoprotein; green tea; obesity; oxidation; wines; antioxidants; cholesterol; caffeine; plasma
AB Background: Metabolic Syndrome, or Syndrome X, is characterized by a set of metabolic and lipid imbalances that greatly increases the risk of developing diabetes and cardiovascular disease. The syndrome is highly prevalent in the United States and worldwide, and treatments are in high demand. ProAlgaZyme, a novel and proprietary freshwater algae infusion in purified water, has been the subject of several animal studies and has demonstrated low toxicity even with chronic administration at elevated doses. The infusion has been used historically for the treatment of several inflammatory and immune disorders in humans and is considered well-tolerated. Here, the infusion is evaluated for its effects on the cardiovascular risk factors present in metabolic syndrome in a randomized double-blind placebo-controlled study involving 60 overweight and obese persons, ages 25-60. All participants received four daily oral doses (I fl oz) of ProAlgaZyme (N = 22) or water placebo (N = 30) for a total of 10 weeks, and were encouraged to maintain their normal levels of physical activity. Blood sampling and anthropometric measurements were taken at the beginning of the study period and after 4, 8 and 10 weeks of treatment. Eight participants did not complete the study. Results: ProAlgaZyme brought about statistically significant (p < 0.001) reductions in the following: weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein and fasting blood glucose levels, accompanied by a significant (p < 0.001) increase in HDL-cholesterol levels over the 10-week study period. The infusion was well-tolerated and no side effects were noted. Conclusion: ProAlgaZyme (4 fl oz daily) consumption resulted in significant reductions in weight and blood glucose levels, while significantly improving serum lipid profiles and reducing markers of inflammation, thus improving cardiovascular risk factors in overweight and obese subjects over a course of 10 weeks with an absence of adverse side effects. Trial Registration: US ClinicalTrials.gov NCT00489333.
C1 Univ Yaounde, Dept Biochem, Lab Nutr & Nutr Biochem, Yaounde, Cameroon.
   Hlth Enhancement Prod Inc, Scottsdale, AZ USA.
   Univ Yaounde, Fac Med & Biomed Sci, Yaounde, Cameroon.
C3 University of Yaounde I; University of Yaounde I
RP Oben, J (corresponding author), Univ Yaounde, Dept Biochem, Lab Nutr & Nutr Biochem, Yaounde, Cameroon.
EM juliusoben@hotmail.com; juliusoben@hotmail.com; juliusoben@hotmail.com; juliusoben@hotmail.com; tiffany@heponline.com; dochildreth@cox.net; tingolia@heponline.com; natprod@aol.com
CR AGBO GA, 2006, PAK J BIOL SCI, V0, P0
   Agbor GA, 2005, J AGR FOOD CHEM, V53, P6819, DOI 10.1021/jf050445c
   ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502
   BACHORIK PS, 1976, CLIN CHEM, V22, P1828
   BROWN RK, 1994, PEDIATR RES, V36, P487, DOI 10.1203/00006450-199410000-00013
   BUCOLO G, 1973, CLIN CHEM, V19, P476
   Combaret L, 2004, BIOCHEM J, V378, P239, DOI 10.1042/BJ20031660
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Dupuy AM, 2003, CLIN CHEM LAB MED, V41, P948, DOI 10.1515/CCLM.2003.144
   Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356
   FRANKEL EN, 1995, J AGR FOOD CHEM, V43, P890, DOI 10.1021/jf00052a008
   Friedewald WT, 1972, CLIN CHEM, V18, P449
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI 10.1172/JCI20042162S
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683
   Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842
   KANNER J, 1994, J AGR FOOD CHEM, V42, P64, DOI 10.1021/jf00037a010
   *KOR NAT STAT OFF, 2001, REP STAT MORT KOR, V0, P0
   Matsuzawa Y, 1999, ANN NY ACAD SCI, V892, P146, DOI 10.1111/j.1749-6632.1999.tb07793.x
   McGill HC, 2002, CIRCULATION, V105, P2712, DOI 10.1161/01.CIR.0000018121.67607.CE
   OBEN J, 2006, LIPIDS HLTH DIS, V0, P5
   RICHMOND W, 1973, CLIN CHEM, V19, P476
   Ristig M, 2003, AIDS PATIENT CARE ST, V17, P439, DOI 10.1089/108729103322395456
   Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9
   *SPSS, 2001, SPSS WIND REL 11 01, V0, P0
   STEINBERG D, 1989, NEW ENGL J MED, V320, P915
   Teissedre PL, 1996, J SCI FOOD AGR, V70, P55, DOI 10.1002/(SICI)1097-0010(199601)70:1<55::AID-JSFA471>3.3.CO;2-O
   Trinder P, 1969, JOURNAL OF CLINICAL PATHOLOGY, V22, P158, DOI 10.1136/jcp.22.2.158
NR 30
TC 15
Z9 21
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-511X
EI 
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD SEP 5
PY 2007
VL 6
IS 
BP 
EP 
DI 10.1186/1476-511X-6-20
PG 9
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 234AC
UT WOS:000251132000001
PM 17803818
DA 2025-04-28
ER

PT J
AU Keast, RSJ
   Riddell, LJ
AF Keast, Russell S. J.
   Riddell, Lynnette J.
TI Caffeine as a flavor additive in soft-drinks
SO APPETITE
LA English
DT Article
DE caffeine; soft-drink; flavor; threshold; psychophysics; obesity
ID dependence; consumption; adolescents; withdrawal; obesity
AB Over 60% of soft-drinks sold in the United States contain caffeine, a mildly addictive psycho-active chemical, as a flavor additive. Using sweeteners as controls, we assessed whether caffeine has flavor activity in a cola soft-drink. A forced-choice triangle discrimination methodology was used to determine detection thresholds of caffeine in sweeteners and a cola beverage. The subjects (n = 30, 28 female, 23 +/- 4 years old) were trained tasters and completed over 1600 discrimination tests during the study. The mean detection thresholds for caffeine in the sweet solutions were: 0.333 +/- 0.1 mM sucrose; 0.467 +/- 0.29mM aspartame; 0.462 +/- 0.3mM sucralose, well below the concentration in common cola beverages (0.55-0.67 mM). A fixed concentration of caffeine, corresponding to the concentration of caffeine in a common cola beverage (0.67 mM) was added to the sweeteners and a non-caffeinated cola beverage. Subjects could distinguish between caffeinated and non-caffeinated sweeteners (p < 0.001), but all subjects failed to distinguish between caffeinated and non-caffeinated cola beverage (p = 1.0). Caffeine has no flavor activity in soft-drinks yet will induce a physiologic and psychologic desire to consume the drink. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Deakin Univ, Sch Exercise & Nutr Sci, Burwood, Vic 3125, Australia.
C3 Deakin University
RP Keast, RSJ (corresponding author), Deakin Univ, Sch Exercise & Nutr Sci, 221 Burwood Highway, Burwood, Vic 3125, Australia.
EM russell.keast@deakin.edu.au
CR Bartoshuk LM, 2000, CHEM SENSES, V25, P447, DOI 10.1093/chemse/25.4.447
   Cowart BJ, 1998, CHEM SENSES, V23, P397, DOI 10.1093/chemse/23.4.397
   Drewnowski A, 2005, AM J CLIN NUTR, V82, P265S, DOI 10.1093/ajcn/82.1.265S
   Ebbeling CB, 2006, PEDIATRICS, V117, P673, DOI 10.1542/peds.2005-0983
   Fried EJ, 2002, JAMA-J AM MED ASSOC, V288, P2181, DOI 10.1001/jama.288.17.2181
   Garrett BE, 1998, PSYCHOPHARMACOLOGY, V139, P195, DOI 10.1007/s002130050704
   GREEN BG, 1993, CHEM SENSES, V18, P683, DOI 10.1093/chemse/18.6.683
   Griffiths RR, 2000, ARCH FAM MED, V9, P727, DOI 10.1001/archfami.9.8.727
   HEISHMAN SJ, 1992, NEUROSCI BIOBEHAV R, V16, P273, DOI 10.1016/S0149-7634(05)80202-7
   Hughes J, 1993, PROBLEMS DRUG DEPEND, V0, P0
   Juliano LM, 2004, PSYCHOPHARMACOLOGY, V176, P1, DOI 10.1007/s00213-004-2000-x
   KEAST R, 2006, IN PRESS CHEM SENSES, V0, P0
   Keast RSJ, 2006, J FOOD SCI, V71, PS567, DOI 10.1111/j.1750-3841.2006.00146.x
   Keast RSJ, 2002, CHEM SENSES, V27, P123, DOI 10.1093/chemse/27.2.123
   Keast SJR, 2003, FOOD QUAL PREFER, V14, P111, DOI 10.1016/S0950-3293(02)00110-6
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   Meilgaard M, 1999, SENSORY EVALUATION TECHNIQUES, V3rd ed., P0
   Mennella JA, 2005, CHEM SENSES, V30, PI242, DOI 10.1093/chemse/bjh204
   Myers KP, 2006, DEV PSYCHOBIOL, V48, P380, DOI 10.1002/dev.20147
   Nehlig A, 1999, NEUROSCI BIOBEHAV R, V23, P563, DOI 10.1016/S0149-7634(98)00050-5
   Oberstar JV, 2002, J CHILD ADOL PSYCHOP, V12, P127, DOI 10.1089/104454602760219162
   *PEPSCO, 1981, PHYS TECHN EFF CAFF, V0, P0
   RICHARDSON NJ, 1995, PHARMACOL BIOCHEM BE, V52, P313, DOI 10.1016/0091-3057(95)00029-V
   Scholey AB, 2004, PSYCHOPHARMACOLOGY, V176, P320, DOI 10.1007/s00213-004-1935-2
   Schuh KJ, 1997, PSYCHOPHARMACOLOGY, V130, P320, DOI 10.1007/s002130050246
   SILVERMAN K, 1992, NEW ENGL J MED, V327, P1109, DOI 10.1056/NEJM199210153271601
   STRAIN EC, 1994, JAMA-J AM MED ASSOC, V272, P1043, DOI 10.1001/jama.272.13.1043
   Striegel-Moore RH, 2006, J PEDIATR-US, V148, P183, DOI 10.1016/j.jpeds.2005.11.025
   Yeomans MR, 2000, APPETITE, V35, P131, DOI 10.1006/appe.2000.0339
NR 29
TC 41
Z9 54
U1 8
U2 78
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0195-6663
EI 1095-8304
J9 APPETITE
JI Appetite
PD JUL 15
PY 2007
VL 49
IS 1
BP 255
EP 259
DI 10.1016/j.appet.2006.11.003
PG 5
WC Behavioral Sciences; Nutrition & Dietetics
SC Behavioral Sciences; Nutrition & Dietetics
GA 184EK
UT WOS:000247623700030
PM 17189661
DA 2025-04-28
ER

PT J
AU Rudelle, S
   Ferruzzi, MG
   Cristiani, I
   Moulin, J
   Mace, K
   Acheson, KJ
   Tappy, L
AF Rudelle, Servane
   Ferruzzi, Mario G.
   Cristiani, Isabelle
   Moulin, Julie
   Mace, Katherine
   Acheson, Kevin J.
   Tappy, Luc
TI Effect of a thermogenic beverage on 24-hour energy metabolism in humans
SO OBESITY
LA English
DT Article
DE 24-hour energy expenditure; fat oxidation; green tea; caffeine; epigallocatechin gallate
ID fat oxidation; green tea; calcium intake; catechin-polyphenols; dietary calcium; caffeine; expenditure; weight; dairy; obesity
AB Objective: To test whether consumption of a beverage containing active ingredients will increase 24-hour energy metabolism in healthy, young, lean individuals. Research Method and Procedures: Thirty-one male and female subjects consumed 3 X 250-mL servings of a beverage containing green tea catechins, caffeine, and calcium for 3 days in a single-center, double-blind, placebo-controlled, cross-over design study. On the 3rd day, 23-hour energy metabolism, extrapolated to 24-hour, was measured in a calorimeter chamber. Blood pressure and heart rate were measured, and total day and night urines were analyzed for urea and catecholamine excretion. Results: Twenty-four-hour energy expenditure (EE) and 24-hour fat oxidation were lower in women than in men (p < 0.0001 and p < 0.015, respectively). Although there were no treatment or treatment/gender effects on substrate oxidation, treatment increased 24-hour EE by 106 +/- 31 kcal/24 hours (p = 0.002), equivalent to 4.7 +/- 1.6 kcal/h (day; p = 0.005) and 3.3 +/- 1.5 kcal/h (night; p = 0.04). No significant differences were observed in hemodynamic parameters. Discussion: The present study provides evidence that consumption of a beverage containing green tea catechins, caffeine, and calcium increases 24-hour EE by 4.6%, but the contribution of the individual ingredients cannot be distinguished. Although this increase is modest, the results are discussed in relation to proposed public health goals, indicating that such modifications are sufficient to prevent weight gain. When consumed regularly as part of a healthy diet and exercise regime, such a beverage may provide benefits for weight control.
C1 Univ Lausanne, Dept Physiol, CH-1005 Lausanne, Switzerland.
   Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA.
   Nestle Res Ctr, CH-1000 Lausanne, Switzerland.
C3 University of Lausanne; Purdue University System; Purdue University; Nestle SA; Nestle Research Center
RP Tappy, L (corresponding author), Univ Lausanne, Dept Physiol, Rue du Bugnon 7, CH-1005 Lausanne, Switzerland.
EM Luc.Tappy@unil.ch
CR Acheson KJ, 2004, AM J CLIN NUTR, V79, P40
   ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Arch JRS, 1996, INT J OBESITY, V20, P191
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Barr SI, 2003, J NUTR, V133, P0
   Benowitz NL, 1995, CLIN PHARMACOL THER, V58, P684, DOI 10.1016/0009-9236(95)90025-X
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Boothby WM, 1923, J PHARMACOL EXP THER, V22, P99
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   Bray GA, 2000, NUTRITION, V16, P953, DOI 10.1016/S0899-9007(00)00424-X
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Davies KM, 2000, J CLIN ENDOCR METAB, V85, P4635, DOI 10.1210/jc.85.12.4635
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DURNIN JVG, 1967, BRIT J NUTR, V21, P681, DOI 10.1079/BJN19670070
   Ferruzzi MG, 2006, FOOD CHEM, V99, P484, DOI 10.1016/j.foodchem.2005.08.010
   Higgins HL, 1915, J PHARMACOL EXP THER, V7, P1
   Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857
   HURNI M, 1982, BRIT J NUTR, V47, P33, DOI 10.1079/BJN19820006
   Jacobsen R, 2005, INT J OBESITY, V29, P292, DOI 10.1038/sj.ijo.0802785
   Komatsu Tatsushi, 2003, JOURNAL OF MEDICAL INVESTIGATION, V50, P170
   LIVESEY G, 1988, AM J CLIN NUTR, V47, P608, DOI 10.1093/ajcn/47.4.608
   Means JH, 1917, ARCH INTERN MED, V19, P832
   Melanson EL, 2003, INT J OBESITY, V27, P196, DOI 10.1038/sj.ijo.802202
   MILLER DS, 1974, P NUTR SOC, V33, P0
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Silva AP, 2005, J NEUROCHEM, V93, P163, DOI 10.1111/j.1471-4159.2004.03005.x
   Teegarden D, 2003, J NUTR, V133, P249S, DOI 10.1093/jn/133.1.249S
   Zemel MB, 2005, OBES RES, V13, P1218, DOI 10.1038/oby.2005.144
   Zemel MB, 2004, AM J CLIN NUTR, V79, P907
   Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132
   Zemel MB, 2004, NUTR REV, V62, P125, DOI 10.1301/nr.2004.apr.125–131
   Zemel MB, 2004, OBES RES, V12, P582, DOI 10.1038/oby.2004.67
   Zemel MB, 2002, J AM COLL NUTR, V21, P146S, DOI 10.1080/07315724.2002.10719212
NR 36
TC 84
Z9 93
U1 2
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD FEB 15
PY 2007
VL 15
IS 2
BP 349
EP 355
DI 10.1038/oby.2007.529
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 212OB
UT WOS:000249605600010
PM 17299107
DA 2025-04-28
ER

PT J
AU Poortvliet, PC
   Bérubé-Parent, S
   Drapeau, V
   Lamarche, B
   Blundell, JE
   Tremblay, A
AF Poortvliet, Peter C.
   Berube-Parent, Sonia
   Drapeau, Vicky
   Lamarche, Benoit
   Blundell, John E.
   Tremblay, Angelo
TI Effects of a healthy meal course on spontaneous energy intake, satiety and palatability
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE appetite control; palatability; energy intake; macronutrients; functional food
ID high-fat diet; weight-loss; green tea; food-intake; caffeine consumption; metabolic-rate; oxidation; expenditure; density; maintenance
AB Many food components can influence satiety or energy intake. Combined together, these food components could represent an interesting dietary strategy in the prevention and treatment of obesity. The aims of this study were: 1) to determine the effect of a functional food in the form of a healthy meal course on subsequent energy intake and satiety; 2) to verify if it is possible to maintain palatability while preserving the satiating effects of the test meal. Thirteen subjects were invited to eat two lunch sessions: healthy and control meal courses (2090 kJ/meal). Anthropometric and ad libitum food intake measurements, and visual analogue scales (VAS) were performed during the two lunch sessions. The healthy main course acutely decreased energy intake during the rest of the meal (-744 kJ, P <= 0.0001) and lipid (-6%, P <= 0.0001) compared with the control meal. VAS ratings during the course of the testing showed a meal effect for hunger, desire to eat and prospective food consumption (P <= 0.05) and a time effect for all appetite sensations (P: <= 0.0001). VAS scores on hunger ratings were lower for the healthy meal (P <= 0.05), whereas fullness ratings were higher shortly after the healthy main course (P <= 0.05). The healthy meal produced a slightly higher palatability rating but this effect was not statistically significant. These results suggest that it is possible to design a healthy meal that decreases spontaneous energy intake and hunger without compromising palatability.
C1 Univ Laval, Dept Social & Prevent Med, Div Kinesiol, Ste Foy, PQ G1K 7P4, Canada.
   Univ Laval, Inst Nutraceut & Funct Foods, Ste Foy, PQ G1K 7P4, Canada.
   Univ Leeds, Inst Psychol & Sci, Psychobiol Grp, Leeds, W Yorkshire, England.
C3 Laval University; Laval University; University of Leeds
RP Tremblay, A (corresponding author), Univ Laval, Dept Social & Prevent Med, Div Kinesiol, Ste Foy, PQ G1K 7P4, Canada.
EM angelo.tremblay@kin.msp.ulaval.ca
CR Anderson JW, 2001, AM J CLIN NUTR, V74, P579
   Bell EA, 1998, AM J CLIN NUTR, V67, P412
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   Doucet E, 2000, INTERNATIONAL JOURNAL OF OBESITY, V24, P0
   Drapeau V, 2000, HANDB EXP PHARM, V149, P237
   DREWNOWSKI A, 1995, AM J CLIN NUTR, V62, P1081, DOI 10.1093/ajcn/62.5.1081S
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Eisenstein J, 2002, NUTR REV, V60, P189, DOI 10.1301/00296640260184264
   Esch T, 2004, NEUROENDOCRINOL LETT, V25, P235
   HILL A J, 1986, NUTRITION AND BEHAVIOR, V3, P133
   *HLTH WELF CAN, 1997, CAN NUTR FIL, V0, P0
   Horgen KB, 2002, HEALTH PSYCHOL, V21, P505, DOI 10.1037/0278-6133.21.5.505
   Howarth NC, 2001, NUTR REV, V59, P129, DOI 10.1111/j.1753-4887.2001.tb07001.x
   Jacqmain M, 2003, AM J CLIN NUTR, V77, P1448, DOI 10.1093/ajcn/77.6.1448
   Johnston CS, 2005, J AM COLL NUTR, V24, P158, DOI 10.1080/07315724.2005.10719460
   Koh-Banerjee P, 2003, P NUTR SOC, V62, P25, DOI 10.1079/PNS2002232
   LISSNER L, 1987, AM J CLIN NUTR, V46, P886, DOI 10.1093/ajcn/46.6.886
   Ludwig DS, 2000, J NUTR, V130, P280S, DOI 10.1093/jn/130.2.280S
   Pereira MA, 2001, PEDIATR CLIN N AM, V48, P969, DOI 10.1016/S0031-3955(05)70351-5
   Pi-Sunyer FX, 1998, OBES RES, V6, P0
   POEHLMAN ET, 1985, MED SCI SPORT EXER, V17, P689, DOI 10.1249/00005768-198512000-00012
   Roberts Susan B, 2003, NUTR CLIN CARE, V6, P20
   Rolls BJ, 1999, AM J CLIN NUTR, V70, P448
   Rolls BJ, 2005, OBES RES, V13, P1052, DOI 10.1038/oby.2005.123
   Rolls BJ, 1999, AM J CLIN NUTR, V69, P863
   Rolls BJ, 1998, AM J CLIN NUTR, V67, P1170, DOI 10.1093/ajcn/67.6.1170
   Rolls ET, 2005, PHYSIOL BEHAV, V85, P45, DOI 10.1016/j.physbeh.2005.04.012
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Skov AR, 1999, INT J OBESITY, V23, P528, DOI 10.1038/sj.ijo.0800867
   Sorensen LB, 2003, INT J OBESITY, V27, P1152, DOI 10.1038/sj.ijo.0802391
   STUBBS RJ, 1995, AM J CLIN NUTR, V62, P316
   TREMBLAY A, 1989, AM J CLIN NUTR, V49, P799, DOI 10.1093/ajcn/49.5.799
   TREMBLAY A, 1995, AM J CLIN NUTR, V62, P639, DOI 10.1093/ajcn/62.3.639
   Tremblay A, 1996, AM J CLIN NUTR, V63, P479, DOI 10.1093/ajcn/63.4.479
   TREMBLAY A, 1988, NUTR RES, V8, P553, DOI 10.1016/S0271-5317(88)80077-0
   TREMBLAY A, 1991, AM J CLIN NUTR, V53, P1134, DOI 10.1093/ajcn/53.5.1134
   WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012
   WADDEN TA, 1989, INT J OBESITY, V13, P39
   Warren JM, 2003, PEDIATRICS, V112, PE414, DOI 10.1542/peds.112.5.e414
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Yoshioka M, 2001, BRIT J NUTR, V85, P203, DOI 10.1079/BJN2000224
   Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132
NR 44
TC 25
Z9 29
U1 0
U2 4
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD MAR 15
PY 2007
VL 97
IS 3
BP 584
EP 590
DI 10.1017/S000711450738135X
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 148MQ
UT WOS:000245079700023
PM 17313722
DA 2025-04-28
ER

PT J
AU Diepvens, K
   Westerterp, KR
   Westerterp-Plantenga, MS
AF Diepvens, Kristel
   Westerterp, Klaas R.
   Westerterp-Plantenga, Margriet S.
TI Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
LA English
DT Review
DE sympathetic nervous system; energy expenditure; body weight; adverse effects
ID sympathetic-nervous-system; body-weight loss; subcutaneous adipose-tissue; energy-restricted diet; resting metabolic-rate; angiogenesis in-vitro; double-blind trial; high-fat diet; red-pepper; food-intake
AB The global prevalence of obesity has increased considerably in the last decade. Tools for obesity management, including caffeine, ephedrine, capsaicin, and green tea have been proposed as strategies for weight loss and weight maintenance, since they may increase energy expenditure and have been proposed to counteract the decrease in metabolic rate that is present during weight loss. A combination of caffeine and ephedrine has shown to be effective in long-term weight management, likely due to different mechanisms that may operate synergistically, e.g., respectively inhibiting the phosphodiesterase-induced degradation of cAMP and enhancing the sympathetic release of catecholamines. However, adverse effects of ephedrine prevent the feasibility of this approach. Capsaicin has been shown to be effective, yet when it is used clinically it requires a strong compliance to a certain dosage, that has not been shown to be feasible yet. Also positive effects on body-weight management have been shown using green tea mixtures. Green tea, by containing both tea catechins and caffeine, may act through inhibition of catechol O-methyl-transferase, and inhibition of phosphodiesterase. Here, the mechanisms may also operate synergistically. In addition, tea catechins have antiangiogenic properties that may prevent development of overweight and obesity. Furthermore, the sympathetic nervous system is involved in the regulation of lipolysis, and the sympathetic innervation of white adipose tissue may play an important role in the regulation of total body fat in general.
C1 Maastricht Univ, Dept Human Biol, NL-6200 MD Maastricht, Netherlands.
C3 Maastricht University
RP Diepvens, K (corresponding author), Maastricht Univ, Dept Human Biol, POB 616, NL-6200 MD Maastricht, Netherlands.
EM K.Diepvens@HB.Unimaas.NL
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   ANDERSSON B, 1991, HYPERTENSION, V18, P783, DOI 10.1161/01.HYP.18.6.783
   Unknown -, 2000, WHO TECH REP SER, V894, P1
   ASTRUP A, 1992, INT J OBESITY, V16, P269
   ASTRUP A, 1985, AM J CLIN NUTR, V42, P83, DOI 10.1093/ajcn/42.1.83
   Astrup A, 2000, ENDOCRINE, V13, P207, DOI 10.1385/ENDO:13:2:207
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   ASTRUP A, 1993, INT J OBESITY, V17, P0
   ASTRUP A, 1995, INT J OBESITY, V19, P0
   Bartness TJ, 1998, AM J PHYSIOL-REG I, V275, PR1399, DOI 10.1152/ajpregu.1998.275.5.R1399
   BAZELMANS J, 1985, METABOLISM, V34, P154, DOI 10.1016/0026-0495(85)90125-8
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Bobbioni-Harsch E, 2004, INT J OBESITY, V28, P906, DOI 10.1038/sj.ijo.0802620
   Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   Bouloumié A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   Bråkenhielm E, 2004, CIRC RES, V94, P1579, DOI 10.1161/01.RES.0000132745.76882.70
   BRAY GA, 1986, FED PROC, V45, P1404
   Bray GA, 2000, INT J OBESITY, V24, PS8, DOI 10.1038/sj.ijo.0801269
   BUKOWIECKI L, 1982, INT J OBESITY, V6, P343
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Chen M D, 1994, ZHONGHUA YI XUE ZA ZHI (TAIPEI), V53, P257
   Choo JJ, 2003, J NUTR BIOCHEM, V14, P671, DOI 10.1016/j.jnutbio.2003.08.005
   Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0
   CURATOLO PW, 1983, ANN INTERN MED, V98, P641, DOI 10.7326/0003-4819-98-5-641
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   Dodt C, 2003, ACTA PHYSIOL SCAND, V177, P351, DOI 10.1046/j.1365-201X.2003.01077.x
   Dodt C, 2000, DIABETES, V49, P1875, DOI 10.2337/diabetes.49.11.1875
   DULLOO AG, 1993, INT J OBESITY, V17, P0
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   DULLOO AG, 1986, INT J OBESITY, V10, P467
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 2004, PHYSIOL BEHAV, V83, P587, DOI 10.1016/j.physbeh.2004.07.028
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1991, INT J OBESITY, V15, P317
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   Dulloo AG, 2002, SCIENCE, V297, P780, DOI 10.1126/science.1074923
   DULLOO AG, 1987, J NUTR, V117, P383, DOI 10.1093/jn/117.2.383
   DULLOO AG, 1986, AM J CLIN NUTR, V43, P388, DOI 10.1093/ajcn/43.3.388
   DULLOO AG, 2001, INT J OBES RELAT M S, V5, P0
   Eikelis N, 2005, EXP PHYSIOL, V90, P673, DOI 10.1113/expphysiol.2005.031385
   Eikelis N, 2004, AM J PHYSIOL-ENDOC M, V286, PE744, DOI 10.1152/ajpendo.00489.2003
   Eikelis N, 2003, HYPERTENSION, V41, P1072, DOI 10.1161/01.HYP.0000066289.17754.49
   Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164
   Fassina G, 2004, CLIN CANCER RES, V10, P4865, DOI 10.1158/1078-0432.CCR-03-0672
   Flechtner-Mors M, 1999, J LAB CLIN MED, V134, P33, DOI 10.1016/S0022-2143(99)90051-3
   GRASSI G, 1995, HYPERTENSION, V25, P560, DOI 10.1161/01.HYP.25.4.560
   Grassi G, 1998, HYPERTENSION, V31, P64, DOI 10.1161/01.HYP.31.1.64
   Haller CA, 2005, CLIN PHARMACOL THER, V77, P560, DOI 10.1016/j.clpt.2005.01.023
   Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502
   Harada U, 2005, J HEALTH SCI, V51, P248, DOI 10.1248/jhs.51.248
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532
   Haynes WG, 1999, HYPERTENSION, V33, P542, DOI 10.1161/01.HYP.33.1.542
   HENRY CJK, 1986, HUM NUTR-CLIN NUTR, V40C, P165
   HOLLANDS MA, 1981, AM J CLIN NUTR, V34, P2291, DOI 10.1093/ajcn/34.10.2291
   Hongu N, 2000, J NUTR, V130, P152, DOI 10.1093/jn/130.2.152
   Horton TJ, 1996, INT J OBESITY, V20, P91
   JANSSON PA, 1992, J CLIN INVEST, V89, P1610, DOI 10.1172/JCI115756
   JUNG RT, 1981, CLIN SCI, V60, P527, DOI 10.1042/cs0600527
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   KAWADA T, 1988, P SOC EXP BIOL MED, V188, P229, DOI 10.3181/00379727-188-2-RC1
   KAWADA T, 1986, J NUTR, V116, P1272, DOI 10.1093/jn/116.7.1272
   KAWADA T, 1986, P SOC EXP BIOL MED, V183, P250
   Kojima-Yuasa A, 2003, LIFE SCI, V73, P1299, DOI 10.1016/S0024-3205(03)00424-7
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   KURPAD AV, 1994, AM J PHYSIOL, V266, PE877, DOI 10.1152/ajpendo.1994.266.6.E877
   Lai HC, 2004, CANCER LETT, V213, P181, DOI 10.1016/j.canlet.2004.04.031
   LANDSBERG L, 1990, J NEUROSCI METH, V34, P179, DOI 10.1016/0165-0270(90)90056-L
   LANDSBERG L, 1981, INT J OBESITY, V5, P79
   LANDSBERG L, 1993, INT J OBES RELAT M S, V1, P0
   LEJEUNE MPG, 2003, BR J NUTR, V90, P1
   MACDONALD IA, 1995, INT J OBES RELAT M S, V7, P0
   Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909
   MCCARGAR LJ, 1988, AM J CLIN NUTR, V47, P932, DOI 10.1093/ajcn/47.6.932
   Molnár D, 2000, INT J OBESITY, V24, P1573, DOI 10.1038/sj.ijo.0801433
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Narkiewicz K, 1998, CIRCULATION, V98, P772, DOI 10.1161/01.CIR.98.8.772
   Ohnuki K, 2001, BIOSCI BIOTECH BIOCH, V65, P2033, DOI 10.1271/bbb.65.2033
   Ohnuki K, 2001, BIOSCI BIOTECH BIOCH, V65, P2735, DOI 10.1271/bbb.65.2735
   Oku N, 2003, BIOL PHARM BULL, V26, P1235, DOI 10.1248/bpb.26.1235
   Osaka T, 2000, NEUROREPORT, V11, P2425, DOI 10.1097/00001756-200008030-00017
   Pasman WJ, 1997, INT J OBESITY, V21, P1143, DOI 10.1038/sj.ijo.0800528
   PASQUALI R, 1985, INT J OBESITY, V9, P93
   PASQUALI R, 1987, INT J OBESITY, V11, P163
   PASQUALI R, 1992, CLIN SCI, V82, P85, DOI 10.1042/cs0820085
   Purdham DM, 2004, AM J PHYSIOL-HEART C, V287, PH2877, DOI 10.1152/ajpheart.00499.2004
   RACOTTA IS, 1994, PHARMACOL BIOCHEM BE, V48, P887, DOI 10.1016/0091-3057(94)90196-1
   Rados Carol, 2004, FDA CONSUM, V38, P6
   Ramsey JJ, 1998, AM J CLIN NUTR, V68, P42, DOI 10.1093/ajcn/68.1.42
   RAVUSSIN E, 1995, INT J OBESITY, V19, P0
   Ray S, 2005, ARCH TOXICOL, V79, P330, DOI 10.1007/s00204-005-0672-6
   Rayner DV, 2001, J MOL MED, V79, P8, DOI 10.1007/s001090100198
   ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403
   ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124
   Roomi MW, 2005, ONCOL REP, V14, P807
   Rumantir MS, 1999, J HYPERTENS, V17, P1125, DOI 10.1097/00004872-199917080-00012
   SAAD MF, 1991, AM J PHYSIOL, V261, PE789, DOI 10.1152/ajpendo.1991.261.6.E789
   Saper RB, 2004, AM FAM PHYSICIAN, V70, P1731
   Sartippour MR, 2004, INT J ONCOL, V25, P193
   Sartippour MR, 2002, INT J ONCOL, V21, P487
   SCHERRER U, 1994, CIRCULATION, V89, P2634, DOI 10.1161/01.CIR.89.6.2634
   Shannon JR, 1999, CLIN SCI, V96, P483, DOI 10.1042/CS19980206
   Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537
   Silha JV, 2005, INT J OBESITY, V29, P1308, DOI 10.1038/sj.ijo.0802987
   SIMONSEN L, 1992, AM J PHYSIOL, V263, PE850, DOI 10.1152/ajpendo.1992.263.5.E850
   Snitker S, 2000, OBES REV, V1, P5, DOI 10.1046/j.1467-789x.2000.00001.x
   SPRAUL M, 1993, J CLIN INVEST, V92, P1730, DOI 10.1172/JCI116760
   Tang FY, 2003, INT J CANCER, V106, P871, DOI 10.1002/ijc.11325
   TOTH MJ, 1994, METABOLISM, V43, P621, DOI 10.1016/0026-0495(94)90205-4
   TOUBRO S, 1993, INT J OBESITY, V17, P0
   TOUBRO S, 1993, INT J OBESITY, V17, P0
   Trayhurn P, 1999, INT J OBESITY, V23, P22, DOI 10.1038/sj.ijo.0800791
   Trayhurn P, 1998, P NUTR SOC, V57, P413, DOI 10.1079/PNS19980060
   TREMBLAY A, 1988, NUTR RES, V8, P553, DOI 10.1016/S0271-5317(88)80077-0
   Trompezinski S, 2003, ARCH DERMATOL RES, V295, P112, DOI 10.1007/s00403-003-0402-y
   Tsi D, 2003, J NUTR SCI VITAMINOL, V49, P437, DOI 10.3177/jnsv.49.437
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   TULP OL, 1986, COMP BIOCHEM PHYS C, V85, P17
   Vansal SS, 1999, BIOCHEM PHARMACOL, V58, P807, DOI 10.1016/S0006-2952(99)00152-5
   vanSoeren M, 1996, J APPL PHYSIOL, V80, P999, DOI 10.1152/jappl.1996.80.3.999
   Vaz M, 1997, CIRCULATION, V96, P3423
   Voros G, 2005, ENDOCRINOLOGY, V146, P4545, DOI 10.1210/en.2005-0532
   WATANABE T, 1987, BIOCHEM BIOPH RES CO, V142, P259, DOI 10.1016/0006-291X(87)90479-7
   WATANABE T, 1988, AM J PHYSIOL, V255, PE23, DOI 10.1152/ajpendo.1988.255.1.E23
   Westerterp-Plantenga MS, 2005, INT J OBESITY, V29, P682, DOI 10.1038/sj.ijo.0802862
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   WHITE JE, 1958, P SOC EXP BIOL MED, V99, P375
   Yamakawa S, 2004, CANCER LETT, V210, P47, DOI 10.1016/j.canlet.2004.03.008
   YOSHIDA T, 1994, INT J OBESITY, V18, P345
   YOSHIDA T, 1988, J NUTR SCI VITAMINOL, V34, P587, DOI 10.3177/jnsv.34.587
   Yoshioka M, 1995, J NUTR SCI VITAMINOL, V41, P647, DOI 10.3177/jnsv.41.647
   Yoshioka M, 1999, BRIT J NUTR, V82, P115, DOI 10.1017/S0007114599001269
   Yoshioka M, 1998, BRIT J NUTR, V80, P503, DOI 10.1017/S0007114598001597
   Yoshioka M, 2001, BRIT J NUTR, V85, P203, DOI 10.1079/BJN2000224
   YOUNG JB, 1992, INT J OBESITY, V16, P959
   Zheng GD, 2004, IN VIVO, V18, P55
NR 140
TC 228
Z9 254
U1 2
U2 76
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
EI 1522-1490
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD JAN 15
PY 2007
VL 292
IS 1
BP R77
EP R85
DI 10.1152/ajpregu.00832.2005
PG 9
WC Physiology
SC Physiology
GA 121QK
UT WOS:000243171900006
PM 16840650
DA 2025-04-28
ER

PT J
AU Riksen, NP
   Bosselaar, M
   Bakker, SJL
   Heine, RJ
   Rongen, GA
   Tack, CJ
   Smits, P
AF Riksen, Niels P.
   Bosselaar, Marlies
   Bakker, Stephan J. L.
   Heine, Robert J.
   Rongen, Gerard A.
   Tack, Cees J.
   Smits, Paul
TI Acute elevation of plasma non-esterified fatty acids increases pulse wave velocity and induces peripheral vasodilation in humans in vivo
SO CLINICAL SCIENCE
LA English
DT Article
DE adenosine; non-esterified fatty acid (NEFA); arterial compliance; blood flow; autonomic nervous system
ID insulin-resistance syndrome; autonomic nervous-system; hyperdynamic circulation; norepinephrine spillover; adenosine; infusion; adolescents; activation; mechanism; children
AB Plasma NEFA (non-esterified fatty acid) concentrations are elevated in patients with obesity. In the present study we first aimed to provide an integral haemodynamic profile of elevated plasma NEFAs by the simultaneous assessment of blood pressure, pulse wave velocity, FBF (forearm blood flow) and sympathetic nervous system activity during acute elevation of NEFAs. Secondly, we hypothesized that NEFA-induced vasodilation is mediated by adenosine receptor stimulation. In a randomized cross-over trial in healthy subjects, Intralipid((R)) was infused for 2 h to elevate plasma NEFAs. Glycerol was administered as the Control infusion. We assessed blood pressure, pulse wave velocity, FBF (using venous occlusion plethysmography) and sympathetic nervous system activity by measurement of noradrenaline and adrenaline. During the last 15 min of Intralipid((R))/Control infusion, the adenosine receptor antagonist caffeine (90 mu g . min(-1) . dl(-1)) was administered into the brachial artery of the non-dominant arm. Compared with Control infusion, lntralipid((R))) increased pulse wave velocity, SBP (systolic blood pressure) and pulse pressure, as well as FBF (from 1.8 +/- 0.2 to 2.7 +/- 0.6 and from 2.3 +/- 0.2 to 2.7 +/- 0.6 ml . min-1 . dl(-1) for Intralipid((R)) compared with Control infusion; P < 0.05, n = 9). Although in a positive control study caffeine attenuated adenosine-induced forearm vasodilation (P < 0.0 1, n = 6), caffeine had no effect on Intralipid((R))-induced vasodilation (P = 0.5). In conclusion, elevation of plasma NEFA levels increased pulse wave velocity, SBP and pulse pressure. FBF was also increased, either by baroreflex-mediated inhibition of the sympathetic nervous system or by a direct vasodilating effect of NEFAs. As the adenosine receptor antagonist caffeine could not antagonize the vasodilator response, this response is not mediated by adenosine receptor stimulation.
C1 Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol Toxicol, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands.
   Univ Groningen, Dept Internal Med, NL-9700 RB Groningen, Netherlands.
   Univ Groningen, Med Ctr, NL-9700 RB Groningen, Netherlands.
   Vrije Univ Amsterdam, Med Ctr, Ctr Diabet, NL-1007 MB Amsterdam, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; University of Groningen; University of Groningen; Vrije Universiteit Amsterdam
RP Riksen, NP (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol Toxicol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM N.Riksen@aig.umcn.nl
CR Bakker SJL, 2001, ATHEROSCLEROSIS, V155, P283, DOI 10.1016/S0021-9150(00)00745-0
   Balakrishnan VS, 1996, AM J PHYSIOL-RENAL, V271, PF374, DOI 10.1152/ajprenal.1996.271.2.F374
   BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252
   CHANG PC, 1991, HYPERTENSION, V18, P56, DOI 10.1161/01.HYP.18.1.56
   CHUA BH, 1977, J BIOL CHEM, V252, P6711
   Ciapaite J, 2005, DIABETES, V54, P944, DOI 10.2337/diabetes.54.4.944
   de Kreutzenberg SV, 2000, J CLIN ENDOCR METAB, V85, P793, DOI 10.1210/jc.85.2.793
   Deussen A, 1999, CIRCULATION, V99, P2041, DOI 10.1161/01.CIR.99.15.2041
   Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001
   Franklin SS, 1999, CIRCULATION, V100, P354, DOI 10.1161/01.CIR.100.4.354
   Fredholm BB, 1999, PHARMACOL REV, V51, P83
   Fugmann A, 2003, CLIN SCI, V105, P715, DOI 10.1042/CS20030036
   Gadegbeku CA, 2002, AM J HYPERTENS, V15, P479, DOI 10.1016/S0895-7061(02)02275-6
   Gokce N, 2001, AM J CARDIOL, V88, P153, DOI 10.1016/S0002-9149(01)01610-1
   GREKIN RJ, 1995, HYPERTENSION, V26, P193, DOI 10.1161/01.HYP.26.1.193
   Grekin RJ, 2005, AM J HYPERTENS, V18, P422, DOI 10.1016/j.amjhyper.2004.10.013
   Grundy SM, 2004, J CLIN ENDOCR METAB, V89, P2595, DOI 10.1210/jc.2004-0372
   Heptulla R, 2001, J CLIN ENDOCR METAB, V86, P90, DOI 10.1210/jc.86.1.90
   Huggett RJ, 2004, HYPERTENSION, V44, P847, DOI 10.1161/01.HYP.0000147893.08533.d8
   JIANG XZ, 1995, CIRCULATION, V91, P1101, DOI 10.1161/01.CIR.91.4.1101
   Kearney MT, 2002, CLIN SCI, V102, P495, DOI 10.1042/cs1020495
   Krebs M, 2001, J CLIN ENDOCR METAB, V86, P2153, DOI 10.1210/jc.86.5.2153
   Lind L, 2000, CLIN SCI, V99, P169, DOI 10.1042/cs0990169
   Magnan C, 1999, J CLIN INVEST, V103, P413, DOI 10.1172/JCI3883
   Manzella D, 2001, J CLIN ENDOCR METAB, V86, P2769, DOI 10.1210/jc.86.6.2769
   MOSER GH, 1989, AM J PHYSIOL, V256, PC799, DOI 10.1152/ajpcell.1989.256.4.C799
   Palatini P, 1999, HYPERTENSION, V33, P769, DOI 10.1161/01.HYP.33.3.769
   Paolisso G, 1998, DIABETOLOGIA, V41, P1127, DOI 10.1007/s001250051041
   Paolisso G, 2000, AM J CLIN NUTR, V72, P723
   Riksen NP, 2005, ARTERIOSCL THROM VAS, V25, P109, DOI 10.1161/01.ATV.0000150651.85907.69
   Rongen GA, 2000, CLIN SCI, V99, P363, DOI 10.1042/CS20000084
   Rongen GA, 1996, EUR J CLIN INVEST, V26, P192, DOI 10.1046/j.1365-2362.1996.110264.x
   Rongen GA, 1997, CLIN SCI, V92, P13, DOI 10.1042/cs0920013
   SCOTT MJ, 1989, J CARDIOVASC PHARM, V13, P125
   Shaltout HA, 2005, J PHARMACOL EXP THER, V314, P1328, DOI 10.1124/jpet.105.086314
   Steinberg HO, 1997, J CLIN INVEST, V100, P1230, DOI 10.1172/JCI119636
   STERN MP, 1992, HYPERTENSION, V20, P802, DOI 10.1161/01.HYP.20.6.802
   Stojiljkovic MP, 2001, AM J PHYSIOL-REG I, V280, PR1674, DOI 10.1152/ajpregu.2001.280.6.R1674
   Tack CJJ, 1996, HYPERTENSION, V28, P426, DOI 10.1161/01.HYP.28.3.426
   Tounian P, 2001, LANCET, V358, P1400, DOI 10.1016/S0140-6736(01)06525-4
   van Popele NM, 2000, DIABETOLOGIA, V43, P665, DOI 10.1007/s001250051356
   WILLEMSEN JJ, 1995, CLIN CHEM, V41, P1455
NR 42
TC 9
Z9 9
U1 0
U2 1
PU PORTLAND PRESS LTD
PI LONDON
PA 1ST FLR, 10 QUEEN STREET PLACE, LONDON, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD JUL 15
PY 2007
VL 113
IS 1-2
BP 33
EP 40
DI 10.1042/CS20060365
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 199EM
UT WOS:000248679000004
PM 17309447
DA 2025-04-28
ER

PT J
AU Mendel, RW
   Hofheins, JE
AF Mendel, Ron W.
   Hofheins, Jennifer E.
TI Metabolic responses to the acute ingestion of two commercially available carbonated beverages: A pilot study
SO JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION
LA English
DT Article
ID green tea; energy-expenditure; physical-activity; catechin-polyphenols; caffeine consumption; blood-pressure; fat oxidation; body-weight; obesity; coffee
AB Background: The purpose of this placebo-controlled, double-blind cross-over study was to compare the effects of two commercially available soft drinks on metabolic rate. Methods: After giving informed consent, twenty healthy men and women were randomly assigned to ingest 12 ounces of Celsius (TM) and, on a separate day, 12 ounces of Diet Coke (R). All subjects completed both trials using a randomized, counterbalanced design. Metabolic rate (via indirect calorimetry) and substrate oxidation (via respiratory exchange ratio) were measured at baseline (pre-ingestion) and at the end of each hour for 3 hours post-ingestion. Results: Two-way ANOVA revealed a significant interaction (p < 0.001) between trials in metabolic rate. Scheffe post-hoc testing indicated that metabolic rate increased by 13.8% (+ 0.6 L/min, p < 0.001) 1 hr post, 14.4% (+ 0.63 L/min, p < 0.001) 2 hr post, and 8.5% (+ 0.37 L/min, p < 0.004) 3 hr post Celsius (TM) ingestion. In contrast, small (similar to 4-6%) but statistically insignificant increases in metabolic rate were noted following Diet Coke (R) ingestion. No differences in respiratory exchange ratio were noted between trials. Conclusion: These preliminary findings indicate Celsius (TM) has thermogenic properties when ingested acutely. The effects of repeated, chronic ingestion of Celsius (TM) on body composition are unknown at this time.
C1 [Mendel, Ron W.; Hofheins, Jennifer E.] Wadsworth Vet Adm Med Ctr, Div Exercise Sci & Sports Nutr, Ohio Res Grp, Wadsworth, OH 44281 USA.
   [Mendel, Ron W.] Mt Union Coll, Dept Human Performance & Sport Management, Alliance, OH 44601 USA.
C3 University System of Ohio; University of Mount Union
RP Mendel, RW (corresponding author), Wadsworth Vet Adm Med Ctr, Div Exercise Sci & Sports Nutr, Ohio Res Grp, Wadsworth, OH 44281 USA.
EM ron@ohioresearchgroup.com; jennifer@ohioresearchgroup.com
FU EliteFx Technologies (Boynton Beach, FL)
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Arciero PJ, 2000, METABOLISM, V49, P101, DOI 10.1016/S0026-0495(00)90888-6
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Bensimhon DR, 2006, AM HEART J, V151, P598, DOI 10.1016/j.ahj.2005.03.005
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Bouckenooghe T, 2006, CURR OPIN CLIN NUTR, V9, P728, DOI 10.1097/01.mco.0000247469.26414.55
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   Catenacci VA, 2007, NAT CLIN PRACT ENDOC, V3, P518, DOI 10.1038/ncpendmet0554
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Compher C, 2006, J AM DIET ASSOC, V106, P881, DOI 10.1016/j.jada.2006.02.009
   DONELLY K, 1992, EUR J APPL PHYSIOL O, V65, P459, DOI 10.1007/BF00243514
   Drewnowski A, 2007, AM J CLIN NUTR, V85, P651, DOI 10.1093/ajcn/85.3.651
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Grzanna R, 2005, J MED FOOD, V8, P125, DOI 10.1089/jmf.2005.8.125
   HIATT HH, 1958, BIOCHIM BIOPHYS ACTA, V28, P645, DOI 10.1016/0006-3002(58)90536-5
   Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857
   KOOT P, 1995, ANN NUTR METAB, V39, P135, DOI 10.1159/000177854
   Lachance PA, 2005, ADV FOOD NUTR RES, V49, P1, DOI 10.1016/S1043-4526(05)49001-4
   Le Masurier GC, 2003, RES Q EXERCISE SPORT, V74, P389, DOI 10.1080/02701367.2003.10609109
   Malik VS, 2006, AM J CLIN NUTR, V84, P274
   Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195
   Noordzij M, 2005, J HYPERTENS, V23, P921, DOI 10.1097/01.hjh.0000166828.94699.1d
   Nurminen ML, 1999, EUR J CLIN NUTR, V53, P831, DOI 10.1038/sj.ejcn.1600899
   Rudelle S, 2007, OBESITY, V15, P349, DOI 10.1038/oby.2007.529
   Sitzman Kathy, 2003, AAOHN J, V51, P404
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
NR 29
TC 7
Z9 7
U1 0
U2 17
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1550-2783
EI 
J9 J INT SOC SPORT NUTR
JI J. Int. Soc. Sport Nutr.
PD SEP 15
PY 2007
VL 4
IS 
BP 
EP 
DI 10.1186/1550-2783-4-7
PG 5
WC Nutrition & Dietetics; Sport Sciences
SC Nutrition & Dietetics; Sport Sciences
GA V17ZD
UT WOS:000207974200001
PM 17908290
DA 2025-04-28
ER

PT J
AU Dray, C
   Daviaud, D
   Guigne, C
   Valet, P
   Castan-Laurell, I
AF Dray, C.
   Daviaud, D.
   Guigne, C.
   Valet, P.
   Castan-Laurell, I.
TI Caffeine reduces TNFα up-regulation in human adipose tissue primary culture
SO JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE adipocytes; stroma vascular fraction; primary culture; IL-6; TNF alpha; gene expression
ID tumor-necrosis-factor; insulin-resistance; obesity; expression; inflammation; activation; induction; release
AB Adipose tissue secretions play an important role in the development of obesity-related pathologies such as diabetes. Through inflammatory cytokines production, adipose tissue stromavascular fraction cells (SVF), and essentially macrophages, promote adipocyte insulin resistance by a paracrine way. Since xanthine family compounds such as caffeine were shown to decrease inflammatory production by human blood cells, we investigated the possible effect of caffeine on Tumor Necrosis Factor alpha (TNF alpha) and Interleukin-6 (IL-6) expression by human adipose tissue primary culture. For that purpose, human subcutaneous adipose tissue obtained from healthy non-obese women (BMI: 26.7 +/- 2.2 kg/m(2)) after abdominal dermolipectomy, was split into explants and cultured for 6 hours with or without caffeine. Three different concentrations of caffeine were tested (0.5 mu g/mL, 5 mu g/mL and 50 mu g/mL). After 6 hours of treatment, explants were subjected to collagenase digestion in order to isolate adipocytes and SVF cells. Then, TNF alpha and IL-6 mRNA were analysed by real-time PCR alternatively in adipocytes and SVF cells. In parallel, we checked gene expression of markers involved in adipocyte differenciation and in SVF cells inflammation and proliferation. Our findings show a strong and dose dependent down-regulation of TNF-alpha gene expression in both adipocyte and SVF cells whereas IL-6 was only down regulated in SVF cells. No effect of caffeine was noticed on the other genes studied. Thus, caffeine, by decreasing TNF alpha expression, could improve adipose tissue inflammation during obesity.
C1 [Dray, C.; Daviaud, D.; Guigne, C.; Valet, P.; Castan-Laurell, I.] INSERM, U858, Toulouse, France.
   [Dray, C.; Daviaud, D.; Guigne, C.; Valet, P.; Castan-Laurell, I.] Univ Toulouse 3, Inst Med Mol Rangueil, Equipe N 3, IFR 31, F-31062 Toulouse, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier
RP Dray, C (corresponding author), INSERM, U858, Toulouse, France.
EM draycedr@toulouse.inserm.fr
CR Bastard JP, 2002, J CLIN ENDOCR METAB, V87, P2084, DOI 10.1210/jc.87.5.2084
   Coppack SW, 2001, P NUTR SOC, V60, P349, DOI 10.1079/PNS2001110
   Dandona P, 1998, J CLIN ENDOCR METAB, V83, P2907, DOI 10.1210/jc.83.8.2907
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   Fève B, 2006, CR BIOL, V329, P587, DOI 10.1016/j.crvi.2006.03.020
   Gesta S, 2003, HORM METAB RES, V35, P158, DOI 10.1055/s-2003-39070
   GHEZZI P, 1991, CYTOKINE, V3, P189, DOI 10.1016/1043-4666(91)90015-6
   Horrigan LA, 2004, INT IMMUNOPHARMACOL, V4, P1409, DOI 10.1016/j.intimp.2004.06.005
   HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271
   HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183
   HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854
   Hube F, 1999, HORM METAB RES, V31, P359, DOI 10.1055/s-2007-978754
   Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, P0
   KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899
   LELO A, 1986, CLIN PHARMACOL THER, V39, P54, DOI 10.1038/clpt.1986.10
   Lim YC, 1997, BIOCHEM SOC T, V25, PS231, DOI 10.1042/bst025231s
   Martin ASG, 2006, AM J CLIN NUTR, V83, P461S, DOI 10.1093/ajcn/83.2.461s
   Ofei F, 1996, DIABETES, V45, P881, DOI 10.2337/diabetes.45.7.881
   Qi C, 2000, P SOC EXP BIOL MED, V223, P128, DOI 10.1046/j.1525-1373.2000.22318.x
   SCANNELL G, 1993, J SURG RES, V54, P281, DOI 10.1006/jsre.1993.1044
   Schreyer SA, 1998, J CLIN INVEST, V102, P402, DOI 10.1172/JCI2849
   SEMMLER J, 1993, IMMUNOLOGY, V78, P520
   Sethi JK, 1999, SEMIN CELL DEV BIOL, V10, P19, DOI 10.1006/scdb.1998.0273
   Taylor CT, 1999, J BIOL CHEM, V274, P19447, DOI 10.1074/jbc.274.27.19447
   Trujillo ME, 2006, ENDOCR REV, V27, P798, DOI 10.1210/er.2006-0033
NR 25
TC 13
Z9 16
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1138-7548
EI 1877-8755
J9 J PHYSIOL BIOCHEM
JI J. Physiol. Biochem.
PD DEC 15
PY 2007
VL 63
IS 4
BP 329
EP 336
DI 10.1007/BF03165764
PG 8
WC Biochemistry & Molecular Biology; Physiology
SC Biochemistry & Molecular Biology; Physiology
GA 279JG
UT WOS:000254350900005
PM 18457008
DA 2025-04-28
ER

PT J
AU Murosaki, S
   Lee, TR
   Muroyama, K
   Shin, ES
   Cho, SY
   Yamamoto, Y
   Lee, SJ
AF Murosaki, Shinji
   Lee, Tae Ryong
   Muroyama, Koutarou
   Shin, Eui Seok
   Cho, Si Young
   Yamamoto, Yoshihiro
   Lee, Sang Jun
TI A combination of caffeine, arginine, soy lsoflavones, and L-carnitine enhances both upolysis and fatty acid oxidation in 3T3-L1 and HepG2 cells in vitro and in KK mice in vivo
SO JOURNAL OF NUTRITION
LA English
DT Article
ID insulin-resistance; citric-acid; body-fat; obesity; protein; lipolysis; exercise; association; adiponectin; clearance
AB To develop an anti-obesity agent containing dietary components, we focused on the mechanisms that enhance both lipolysis and fatty acid oxidation. Caffeine and arginine (CA), a nonselective adenosine-receptor antagonist and an inducer of lipolytic hormone, respectively, were used to stimulate lipolysis. Soy isoflavones and L-camiline (SL), stimulators of carnitine palmitoyl transferase 1A and a cofactor for P-oxidation of fatty acids, respectively, were used to enhance fatty acid oxidation. Effects of a combination of CA and SL (CASL) on lipid metabolism were studied in vitro and in vivo. During 3T3-L1 differentiation, lipid accumulation was significantly lower in cells treated with CASL (50 mu mol/L, 1 mmol/L, 1 mu mol/L, and 1 mmol/L, respectively) compared with each alone. Lipolysis was also significantly greater in 3T3-L1 adipocytes treated with CASL (50 mu mol/L, I mmol/L, 10 mu mol/L and 0.5 mmol/L, respectively) compared with each alone. In addition, treatment with higher concentrations of CASL (2 mmol/L, 1 mmol/L, 10 mu mol/L, and 1 mmol/L, respectively) significantly enhanced beta-oxiclation in HepG2 cells. The effects of CASL-containing diets (250 mg, 6 g, 200 mg, and 1.5 g/kg diet, respectively) were studied in vivo. When KK mice were food deprived for 48 In and subsequently refed a fat-free diet for 72 h, hepatic triglyceride (TG) accumulation was significantly lower in mice fed CASL compared with the control mice. In addition, after obese KK mice were fed a low-fat diet for 2 wk, adipose tissue weights were significantly lower in those fed CASL, but not CA or SL alone, compared with the control mice. Plasma and liver TG levels were also lower in mice fed CASL than in the control mice. These results suggest that CASL is effective for controlling obesity.
C1 House Wellness Foods Corp, Dept Res & Dev, Itami, Hyogo 6640011, Japan.
   AmorePacific Corp, R&D Ctr, Yongin 449729, Gyeonggi Do, South Korea.
C3 Samsung
RP Murosaki, S (corresponding author), House Wellness Foods Corp, Dept Res & Dev, Itami, Hyogo 6640011, Japan.
EM Murosaki_Shinji@house-wf.co.jp
CR Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   DODD SL, 1993, SPORTS MED, V15, P14, DOI 10.2165/00007256-199315010-00003
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798
   Furuyashiki T, 2004, BIOSCI BIOTECH BIOCH, V68, P2353, DOI 10.1271/bbb.68.2353
   HARPER AE, 1959, J NUTR, V68, P405, DOI 10.1093/jn/68.3.405
   Horowitz JF, 2000, AM J PHYSIOL-ENDOC M, V278, PE1144, DOI 10.1152/ajpendo.2000.278.6.E1144
   IRITANI N, 1986, J NUTR, V116, P190, DOI 10.1093/jn/116.2.190
   Jocken JWE, 2007, INT J OBESITY, V31, P813, DOI 10.1038/sj.ijo.0803499
   KALKHOFF RK, 1973, NEW ENGL J MED, V289, P465, DOI 10.1056/NEJM197308302890907
   Kim S, 2004, MOL CELL ENDOCRINOL, V220, P51, DOI 10.1016/j.mce.2004.03.011
   Koutsari C, 2006, J LIPID RES, V47, P1643, DOI 10.1194/jlr.R600011-JLR200
   Kuhajda FP, 2005, TRENDS PHARMACOL SCI, V26, P541, DOI 10.1016/j.tips.2005.09.002
   Langin D, 2006, PHARMACOL RES, V53, P482, DOI 10.1016/j.phrs.2006.03.009
   Mannino DM, 2006, INT J OBESITY, V30, P6, DOI 10.1038/sj.ijo.0803145
   McCarthy MF, 2004, MED HYPOTHESES, V63, P1065, DOI 10.1016/j.mehy.2002.11.002
   Mittendorfer B, 2004, AM J PHYSIOL-ENDOC M, V286, PE354, DOI 10.1152/ajpendo.00301.2003
   Muroyama K, 2003, J NUTR SCI VITAMINOL, V49, P56, DOI 10.3177/jnsv.49.56
   Muroyama K, 2003, BIOSCI BIOTECH BIOCH, V67, P2325, DOI 10.1271/bbb.67.2325
   NURJHAN N, 1988, METABOLISM, V37, P386, DOI 10.1016/0026-0495(88)90140-0
   Park HyunWoo Park HyunWoo, 2006, NUTRITIONAL SCIENCES, V9, P179
   Parks EJ, 1999, J CLIN INVEST, V104, P1087, DOI 10.1172/JCI6572
   Schiffelers SLH, 2001, J CLIN ENDOCR METAB, V86, P2191, DOI 10.1210/jc.86.5.2191
   Shin ES, 2006, EUR J NUTR, V45, P159, DOI 10.1007/s00394-005-0576-5
   Shin ES, 2007, J NUTR, V137, P1127, DOI 10.1093/jn/137.5.1127
   Statnick M A, 2000, INT J EXP DIABETES RES, V1, P81, DOI 10.1155/EDR.2000.81
   Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899
   van Baak MA, 1999, INT J OBESITY, V23, PS11, DOI 10.1038/sj.ijo.0800879
   Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102
   Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
NR 33
TC 49
Z9 56
U1 0
U2 8
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD OCT 15
PY 2007
VL 137
IS 10
BP 2252
EP 2257
DI 10.1093/jn/137.10.2252
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 213XU
UT WOS:000249701400014
PM 17885007
DA 2025-04-28
ER

PT J
AU Orfanos, P
   Naska, A
   Trichopoulos, D
   Slimani, N
   Ferrari, P
   van Bakel, M
   Deharveng, G
   Overvad, K
   Tionneland, A
   Halkjær, J
   de Magistris, MS
   Tumino, R
   Pala, V
   Sacerdote, C
   Masala, G
   Skeie, G
   Engeset, D
   Lund, E
   Jakszyn, P
   Barricarte, A
   Chirlaque, MD
   Martinez-Garcia, C
   Amiano, P
   Quiros, JR
   Bingham, S
   Welch, A
   Spencer, EA
   Key, TJ
   Rohrmann, S
   Linseisen, J
   Ray, J
   Boeing, H
   Peeters, PH
   Bueno-De-Mesquita, HB
   Ocke, M
   Johansson, I
   Johansson, G
   Berglund, G
   Manjer, J
   Boutron-Ruault, MC
   Touvier, M
   Clavel-Chapelon, F
   Trichopoulou, A
AF Orfanos, Philippos
   Naska, Androniki
   Trichopoulos, Dimitrios
   Slimani, Nadia
   Ferrari, Pietro
   van Bakel, Marit
   Deharveng, Genevieve
   Overvad, Kim
   Tionneland, Anne
   Halkjaer, Jytte
   de Magistris, Maria Santucci
   Tumino, Rosario
   Pala, Valeria
   Sacerdote, Carlotta
   Masala, Giovanna
   Skeie, Guri
   Engeset, Dagrun
   Lund, Eiliv
   Jakszyn, Paula
   Barricarte, Aurelio
   Chirlaque, Maria-Dolores
   Martinez-Garcia, Carmen
   Amiano, Pilar
   Quiros, J. Ramon
   Bingham, Sheila
   Welch, Ailsa
   Spencer, Elizabeth A.
   Key, Timothy J.
   Rohrmann, Sabine
   Linseisen, Jakob
   Ray, Jennifer
   Boeing, Heiner
   Peeters, Petra H.
   Bueno-De-Mesquita, H. Bas
   Ocke, Marga
   Johansson, Ingegerd
   Johansson, Gerd
   Berglund, Goran
   Manjer, Jonas
   Boutron-Ruault, Marie-Christine
   Touvier, Mathilde
   Clavel-Chapelon, Francoise
   Trichopoulou, Antonia
TI Eating out of home and its correlates in 10 European countries.: The European Prospective Investigation into Cancer and Nutrition (EPIC) study
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE eating out of home; diet; energy intake; eating locations; 24-hour dietary recall; adults; EPIC
ID body-mass index; united-states; energy-intake; young-adults; food; obesity; trends; diet; association; consumption
AB Objective: To compare the average out-of-home (OH) consumption of foods and beverages, as well as energy intake, among populations from 10 European countries and to describe the characteristics of substantial OH caters, as defined for the purpose of the present study, in comparison to other individuals. Design: Cross-sectional study. Dietary data were collected through single 24-hour dietary recalls, in which the place of consumption was recorded. For the present study, substantial OH eaters were defined as those who consumed more than 25% of total daily energy intake at locations other than the household premises. Mean dietary intakes and the proportion of substantial OH eaters are presented by food group and country. Logistic regression analyses were used to estimate the odds of being a substantial OH eater in comparison to not being one, using mutually adjusted possible non-dietary determinants. Setting: Ten European countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). Subjects: The subjects were 34 270 individuals, 12 537 men and 21733 women, aged 35-74 years. Results: The fraction of energy intake during OH eating was generally higher in northern European countries than in the southern ones. Among the food and beverage groups, those selectively consumed outside the home were coffee/tea/waters and sweets and, to a lesser extent, cereals, meats, added lipids and vegetables. Substantial OH eating was positively associated with energy intake and inversely associated with age and physical activity. Substantial OH eating was less common among the less educated compared with the more educated, and more common during weekdays in central and north Europe and during the weekend in south Europe. Conclusions: Eating outside the home was associated with sedentary lifestyle and increased energy intake; it was more common among the young and concerned in particular coffee/tea/waters and sweets.
C1 [Orfanos, Philippos; Naska, Androniki; Trichopoulou, Antonia] Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens 11527, Greece.
   [Slimani, Nadia; Ferrari, Pietro; van Bakel, Marit; Deharveng, Genevieve] Int Agcy Res Canc, Nutr Hormones Grp, F-69372 Lyon, France.
   [Overvad, Kim] Aarhus Univ Hosp, Aalborg Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark.
   [Tionneland, Anne; Halkjaer, Jytte] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark.
   [de Magistris, Maria Santucci] Univ Naples Federico II, Dept Clin & Expt Med, Naples, Italy.
   [Tumino, Rosario] Azienda Osped Civile MP Arezzo, Canc Registry, Ragusa, Italy.
   [Pala, Valeria] Natl Canc Inst, Nutr Epidemiol Unit, I-20133 Milan, Italy.
   [Sacerdote, Carlotta] CPO Piemonte, Turin, Italy.
   [Masala, Giovanna] CSPO Sci Inst Tuscany, Mol & Nutrit Epidemiol Unit, Florence, Italy.
   [Skeie, Guri; Engeset, Dagrun; Lund, Eiliv] Univ Tromso, Inst Community Med, N-9001 Tromso, Norway.
   [Jakszyn, Paula] Catalan Inst Oncol, Dept Epidemiol, Barcelona, Spain.
   [Jakszyn, Paula] Catalan Inst Oncol, Canc Registry, Barcelona, Spain.
   [Barricarte, Aurelio] Publ Hlth Inst Navarra, Pamplona, Spain.
   [Chirlaque, Maria-Dolores] Murcia Hlth Council, Dept Epidemiol, Murcia, Spain.
   [Martinez-Garcia, Carmen] Andalusian Sch Publ Hlth, Granada, Spain.
   [Amiano, Pilar] Dept Publ Hlth Gipuzkoa, Donostia San Sebastian, Spain.
   [Quiros, J. Ramon] Publ Hlth & Hlth Planning Directorate, Asturias, Spain.
   [Bingham, Sheila; Welch, Ailsa] MRC Dunn Human Nutr Unit, Cambridge, England.
   [Bingham, Sheila; Welch, Ailsa] Univ Cambridge, Dept Publ Hlth & Primary Care, MRC Ctr Nutrit Epidemiol Canc Prevent & Survival, Cambridge CB2 1TN, England.
   [Spencer, Elizabeth A.; Key, Timothy J.] Univ Oxford, Canc Res UK Epidemiol Unit, Oxford, England.
   [Rohrmann, Sabine; Linseisen, Jakob] German Canc Res Ctr, Div Clin Epidemiol, D-6900 Heidelberg, Germany.
   [Ray, Jennifer; Boeing, Heiner] German Inst Human Nutr, Dept Epidemiol, Potsdam, Germany.
   [Peeters, Petra H.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Bueno-De-Mesquita, H. Bas; Ocke, Marga] Natl Inst Publ Hlth & Environm, Canc Epidemiol Ctr Nutr & Hlth, NL-3720 BA Bilthoven, Netherlands.
   [Johansson, Ingegerd] Umea Univ, Dept Odontol, Cardiol Sect, S-90187 Umea, Sweden.
   [Johansson, Ingegerd] Umea Univ, Dept Publ Hlth & Med, Sect Nutrit Res, S-90187 Umea, Sweden.
   [Johansson, Gerd] Umea Univ, Dept Publ Hlth & Med, Sect Nutrit Res, S-90187 Umea, Sweden.
   [Berglund, Goran; Manjer, Jonas] Univ Hosp, Malmo Diet & Canc Study, Malmo, Sweden.
   [Boutron-Ruault, Marie-Christine; Touvier, Mathilde; Clavel-Chapelon, Francoise] Inst Gustave Roussy, INSERM, E3N EPIC Grp, F-94805 Villejuif, France.
C3 National & Kapodistrian University of Athens; Athens Medical School; World Health Organization; International Agency for Research on Cancer (IARC); Aalborg University; Aalborg University Hospital; Aarhus University; Danish Cancer Society; University of Naples Federico II; Civile M.P. Arezzo Hospital; Fondazione IRCCS Istituto Nazionale Tumori Milan; Centro di Riferimento per Epidemiologia e la Prevenzione Oncologica in Piemonte; UiT The Arctic University of Tromso; Institut Catala d'Oncologia; Institut Catala d'Oncologia; Public Health Institute of Navarra; Murcia Regional Health Council; Escuela Andaluza de Salud Publica; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Cambridge; University of Oxford; Cancer Research UK; Helmholtz Association; German Cancer Research Center (DKFZ); Leibniz Association; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Utrecht University; Utrecht University Medical Center; Netherlands National Institute for Public Health & the Environment; Umea University; Umea University; Umea University; Lund University; Skane University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy
RP Trichopoulou, A (corresponding author), Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens 11527, Greece.
EM antonia@nut.uoa.gr
CR Agudo A, 2002, PUBLIC HEALTH NUTR, V5, P1179, DOI 10.1079/PHN2002398
   Armitage P, 2001, STAT METHODS MED RES, V4th, P0
   Bell AC, 2004, EUR J CLIN NUTR, V58, P258, DOI 10.1038/sj.ejcn.1601775
   Binkley JK, 2000, INT J OBESITY, V24, P1032, DOI 10.1038/sj.ijo.0801356
   Burns C, 2002, PUBLIC HEALTH NUTR, V5, P441, DOI 10.1079/PHN2001316
   Buzzard M, 1998, NUTRITIONAL EPIDEMIOLOGY, VSecond, P50
   Charrondiere UR, 2002, J FOOD COMPOS ANAL, V15, P435, DOI 10.1006/jfca.2002.1089
   Clemens LHE, 1999, J AM DIET ASSOC, V99, P442, DOI 10.1016/S0002-8223(99)00107-8
   Ferrari P, 2002, PUBLIC HEALTH NUTR, V5, P1329, DOI 10.1079/PHN2002409
   French SA, 2000, INT J OBESITY, V24, P1353, DOI 10.1038/sj.ijo.0801429
   Gillis LJ, 2003, J AM COLL NUTR, V22, P539, DOI 10.1080/07315724.2003.10719333
   GREGORY J, 1990, DIETARY NUTR SURVEY, V0, P218
   Guthrie JF, 2002, J NUTR EDUC BEHAV, V34, P140, DOI 10.1016/S1499-4046(06)60083-3
   Haftenberger M, 2002, PUBLIC HEALTH NUTR, V5, P1163, DOI 10.1079/PHN2002397
   HAINES PS, 1992, J AM DIET ASSOC, V92, P698
   Harnack LJ, 2000, AM J CLIN NUTR, V71, P1478
   Heitmann BL, 2000, INT J OBESITY, V24, P435, DOI 10.1038/sj.ijo.0801176
   Jabs J, 2006, APPETITE, V47, P196, DOI 10.1016/j.appet.2006.02.014
   Jahns L, 2001, J PEDIATR-US, V138, P493, DOI 10.1067/mpd.2001.112162
   James WilliamPT, 1990, HUMAN ENERGY REQUIRE, V0, P0
   Jeffery RW, 1998, AM J PUBLIC HEALTH, V88, P277, DOI 10.2105/AJPH.88.2.277
   Kant AK, 2004, PREV MED, V38, P243, DOI 10.1016/j.ypmed.2003.10.004
   Kearney JM, 2001, PUBLIC HEALTH NUTR, V4, P1117, DOI 10.1079/PHN2001193
   Lafay L, 1997, INT J OBESITY, V21, P567, DOI 10.1038/sj.ijo.0800443
   LeFrancois P, 1996, EUR J CLIN NUTR, V50, P826
   LIN BH, 1999, AGR INFORM B, V749, P1
   LUTKEPOHL H, 1991, INTRO MULTIPLE TIMES, V0, PCH4
   Ma YS, 2003, AM J EPIDEMIOL, V158, P85, DOI 10.1093/aje/kwg117
   McCrory MA, 1999, OBES RES, V7, P564, DOI 10.1002/j.1550-8528.1999.tb00715.x
   Nielsen AJ, 2003, JAMA-J AM MED ASSOC, V289, P450
   Nielsen SJ, 2002, PREV MED, V35, P107, DOI 10.1006/pmed.2002.1037
   Nielsen SJ, 2002, OBES RES, V10, P370, DOI 10.1038/oby.2002.51
   Popkin BM, 1999, APPETITE, V32, P8, DOI 10.1006/appe.1998.0190
   *REG GEN ENGL WAL, 1978, OPCS SERIES, V1, P0
   Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394
   Riboli E, 1997, INT J EPIDEMIOL, V26, PS6, DOI 10.1093/ije/26.suppl_1.S6
   Roos E, 2004, PUBLIC HEALTH NUTR, V7, P53, DOI 10.1079/PHN2003511
   *SHRAPN BIS, 1995, FAST FOOD AUSTR 1995, V0, P0
   Slimani N, 2002, PUBLIC HEALTH NUTR, V5, P1125, DOI 10.1079/PHN2002395
   Slimani N, 1999, COMPUT METH PROG BIO, V58, P251, DOI 10.1016/S0169-2607(98)00088-1
   SLIMANI N, 2007, IN PRESS EUROPEAN J, V0, P0
   Taveras EM, 2005, PEDIATRICS, V116, PE518, DOI 10.1542/peds.2004-2732
   Willett W, 1998, NUTRITIONAL EPIDEMIOLOGY, V0, PP302, DOI 10.1093/acprof:oso/9780199754038.001.0001
   Willett W, 1998, NUTRITIONAL EPIDEMIOLOGY, V0, P33
   World Health Organization Expert Committee, 1995, PHYSICAL STATUS: THE USE AND INTERPRETATION OF ANTHROPOMETRY, V0, P0
   Zizza C, 2001, PREV MED, V32, P303, DOI 10.1006/pmed.2000.0817
NR 46
TC 136
Z9 155
U1 0
U2 24
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD DEC 15
PY 2007
VL 10
IS 12
BP 1515
EP 1525
DI 10.1017/S1368980007000171
PG 11
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA 245UC
UT WOS:000251963300015
PM 17582244
DA 2025-04-28
ER

PT J
AU Nagao, T
   Hase, T
   Tokimitsu, I
AF Nagao, Tomonori
   Hase, Tadashi
   Tokimitsu, Ichiro
TI A green tea extract high in catechins reduces body fat and cardiovascular risks in humans
SO OBESITY
LA English
DT Article
DE tea polyphenol; adiposity; serum cholesterol; blood pressure; metabolic syndrome
ID metabolic syndrome; energy-expenditure; polyphenols; adiponectin; oxidation; ingestion; caffeine; obesity; rich; men
AB Objective: The body fat reducing effect and reduction of risks for cardiovascular disease by a green tea extract (GTE) high in catechins was investigated in humans with typical lifestyles. Research Methods and Procedures: Japanese women and men with visceral fat-type obesity were recruited for the trial. After a 2-week diet run-in period, a 12-week double-blind parallel multicenter trial was performed, in which the subjects ingested green tea containing 583 mg of catechins (catechin group) or 96 mg of catechins (control group) per day. Randomization was stratified by gender and body mass index at each medical institution. The subjects were instructed to maintain their usual dietary intake and normal physical activity. Results: Data were analyzed using per-protocol samples of 240 subjects (catechin group; n = 123, control group; n = 117). Decreases in body weight, body mass index, body fat ratio, body fat mass, waist circumference, hip circumference, visceral fat area, and subcutaneous fat area were found to be greater in the catechin group than in the control group. A greater decrease in systolic blood pressure (SBP) was found in the catechin group compared with the control group for subjects whose initial SBP was 130 mm Hg or higher. Low-density lipoprotein (LDL) cholesterol was also decreased to a greater extent in the catechin group. No adverse effect was found. Discussion: The continuous ingestion of a GTE high in catechins led to a reduction in body fat, SBP, and LDL cholesterol, suggesting that the ingestion of such an extract contributes to a decrease in obesity and cardiovascular disease risks.
C1 Kao Corp, Hlth Care Food Res Labs, Sumida Ku, Tokyo 1318501, Japan.
C3 KAO Corporation
RP Nagao, T (corresponding author), Kao Corp, Hlth Care Food Res Labs, Sumida Ku, 2-1-3 Bunka, Tokyo 1318501, Japan.
EM nagao.tomonori@kao.co.jp
CR Abe I, 2000, BIOCHEM BIOPH RES CO, V268, P767, DOI 10.1006/bbrc.2000.2217
   Ajay M, 2003, LIFE SCI, V74, P603, DOI 10.1016/j.lfs.2003.06.039
   Alexander CM, 2003, DIABETES, V52, P1210, DOI 10.2337/diabetes.52.5.1210
   Unknown -, 2001, GUID DOC US IN VITR, V0, P0
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Fujishima M, 2001, HYPERTENS RES, V24, P613
   Harada U, 2005, J HEALTH SCI, V51, P248, DOI 10.1248/jhs.51.248
   Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126
   Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683
   *KAG NUTR U PRESS, 2000, 4 REV STAND TABL FOO, V0, P0
   Kanno T, 1997, JPN J MED PHARM SCI, V37, P635
   Lin JK, 1998, J AGR FOOD CHEM, V46, P3635, DOI 10.1021/jf980223x
   Matsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF
   Matsuzawa Y, 2005, J JPN SOC INT MED, V94, P188, DOI 10.5551/JAT.12.301
   McKay DL, 2002, J AM COLL NUTR, V21, P1
   *MIN HLTH LAB WELF, 2004, NAT NUTR SURV JAP 20, V0, P0
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagaretani H, 2001, DIABETES CARE, V24, P2127, DOI 10.2337/diacare.24.12.2127
   Nozawa A, 2002, J NUTR FOOD, V5, P1
   TOKUNAGA K, 1983, INT J OBESITY, V7, P437
NR 24
TC 383
Z9 423
U1 3
U2 112
PU NORTH AMER ASSOC STUDY OBESITY
PI SILVER SPRING
PA 8630 FENTON ST, SUITE 918, SILVER SPRING, MD 20910 USA
SN 1930-7381
EI 
J9 OBESITY
JI Obesity
PD JUN 15
PY 2007
VL 15
IS 6
BP 1473
EP 1483
DI 10.1038/oby.2007.176
PG 11
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 180ZG
UT WOS:000247405900017
PM 17557985
DA 2025-04-28
ER

PT J
AU Boschmann, M
   Thielecke, F
AF Boschmann, Michael
   Thielecke, Frank
TI The effects of epigallocatechin-3-gallate on thermogenesis and fat oxidation in obese men: A pilot study
SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
LA English
DT Article; Proceedings Paper
DE epigallocatechin gallate; fat oxidation; energy expenditure
ID green tea; energy-expenditure; metabolic-rate; substrate utilization; adipose-tissue; caffeine; ephedrine; women; consumption; inhibition
AB Objectives: The development of obesity is characterized by an increase in adipose tissue mass and by concomitant and profound changes in almost all organ functions leading to diseases such as hypertension, diabetes mellitus and coronary heart disease. Recent data from human studies indicate that the consumption of green tea and green tea extracts may help reduce body weight, mainly body fat, by increasing postprandial thermogenesis and fat oxidation. However, human studies investigating the metabolic effects of the most predominant tea catechin, EGCG, alone are absent. Methods: In a randomized double blind, placebo-controlled, cross-over pilot study, six overweight men were given 300 mg EGCG/d for 2d. Fasting and postprandial changes in energy expenditure (EE) and substrate oxidation were assessed. Results: Resting EE did not differ significantly between EGCG and placebo treatments, although during the first postprandial monitoring phase, respiratory quotient (RQ) values were significantly lower with EGCG compared to the placebo. Conclusions: These findings suggest that EGCG alone has the potential to increase fat oxidation in men and may thereby contribute to the anti-obesity effects of green tea. However, more studies with a greater sample size and a broader range of age and BMI are needed to define the optimum dose.
C1 Univ Med Berlin, Franz Volhard Ctr Clin Res, D-13125 Berlin, Germany.
   HELIOS Clin Berlin Buch, Berlin, Germany.
   DSM Nutr Prod, Basel, Switzerland.
C3 Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; DSM NV
RP Boschmann, M (corresponding author), Univ Med Berlin, Franz Volhard Ctr Clin Res, Charite Campus Buch, D-13125 Berlin, Germany.
EM michael.boschmann@charite.de
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Arch JRS, 1996, INT J OBESITY, V20, P191
   Arciero PJ, 2000, METABOLISM, V49, P101, DOI 10.1016/S0026-0495(00)90888-6
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Balentine DA, 1997, CRIT REV FOOD SCI, V37, P693, DOI 10.1080/10408399709527797
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   Boschmann M, 2005, HYPERTENSION, V46, P130, DOI 10.1161/01.HYP.0000171477.63859.b2
   Boschmann M, 2003, J CLIN ENDOCR METAB, V88, P6015, DOI 10.1210/jc.2003-030780
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   DULLOO AG, 1993, INT J OBESITY, V17, P0
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Dulloo AG, 1998, BRIT J NUTR, V80, P493, DOI 10.1017/S0007114598001573
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   DULLOO AG, 1993, NUTRITION, V9, P366
   FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   HENRY CJK, 1986, HUM NUTR-CLIN NUTR, V40C, P165
   Horton TJ, 1996, INT J OBESITY, V20, P91
   Jordan J, 2000, CIRCULATION, V101, P504, DOI 10.1161/01.CIR.101.5.504
   Jordan J, 2004, CIRCULATION, V109, P1823, DOI 10.1161/01.CIR.0000126283.99195.37
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Komatsu Tatsushi, 2003, JOURNAL OF MEDICAL INVESTIGATION, V50, P170
   Landsteiner K, 1929, J IMMUNOL, V17, P1
   Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Ten S, 2004, J CLIN ENDOCR METAB, V89, P2526, DOI 10.1210/jc.2004-0276
   TOUBRO S, 1993, INT J OBESITY, V17, P0
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   Wei M, 1996, AM J EPIDEMIOL, V144, P1058, DOI 10.1093/oxfordjournals.aje.a008878
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409
   Yoshioka M, 1998, BRIT J NUTR, V80, P503, DOI 10.1017/S0007114598001597
   Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9
NR 41
TC 137
Z9 150
U1 0
U2 35
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0731-5724
EI 1541-1087
J9 J AM COLL NUTR
JI J. Am. Coll. Nutr.
PD AUG 15
PY 2007
VL 26
IS 4
BP 389S
EP 395S
DI 10.1080/07315724.2007.10719627
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 217PP
UT WOS:000249960100013
PM 17906192
DA 2025-04-28
ER

